<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T08:25:23Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10411362" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10411362</identifier>
        <datestamp>2023-08-10</datestamp>
        <setSpec>canjpsych</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Can J Psychiatry</journal-id>
              <journal-id journal-id-type="iso-abbrev">Can J Psychiatry</journal-id>
              <journal-id journal-id-type="publisher-id">CPA</journal-id>
              <journal-id journal-id-type="hwp">spcpa</journal-id>
              <journal-title-group>
                <journal-title>Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0706-7437</issn>
              <issn pub-type="epub">1497-0015</issn>
              <publisher>
                <publisher-name>SAGE Publications</publisher-name>
                <publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10411362</article-id>
              <article-id pub-id-type="pmcid">PMC10411362</article-id>
              <article-id pub-id-type="pmc-uid">10411362</article-id>
              <article-id pub-id-type="pmid">36519188</article-id>
              <article-id pub-id-type="pmid">36519188</article-id>
              <article-id pub-id-type="doi">10.1177/07067437221145013</article-id>
              <article-id pub-id-type="publisher-id">10.1177_07067437221145013</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Original Research</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7969-9998</contrib-id>
                  <name>
                    <surname>Bastien</surname>
                    <given-names>Gabriel</given-names>
                  </name>
                  <degrees>BSc</degrees>
                  <xref rid="aff1-07067437221145013" ref-type="aff">1</xref>
                  <xref rid="aff2-07067437221145013" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2787-2792</contrib-id>
                  <name>
                    <surname>McAnulty</surname>
                    <given-names>Christina</given-names>
                  </name>
                  <degrees>MSc</degrees>
                  <xref rid="aff1-07067437221145013" ref-type="aff">1</xref>
                  <xref rid="aff2-07067437221145013" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ledjiar</surname>
                    <given-names>Omar</given-names>
                  </name>
                  <degrees>MSc</degrees>
                  <xref rid="aff3-07067437221145013" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Socias</surname>
                    <given-names>M. Eugenia</given-names>
                  </name>
                  <degrees>MD, MSc</degrees>
                  <xref rid="aff4-07067437221145013" ref-type="aff">4</xref>
                  <xref rid="aff5-07067437221145013" ref-type="aff">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Le Foll</surname>
                    <given-names>Bernard</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref rid="aff6-07067437221145013" ref-type="aff">6</xref>
                  <xref rid="aff7-07067437221145013" ref-type="aff">7</xref>
                  <xref rid="aff8-07067437221145013" ref-type="aff">8</xref>
                  <xref rid="aff9-07067437221145013" ref-type="aff">9</xref>
                  <xref rid="aff10-07067437221145013" ref-type="aff">10</xref>
                  <xref rid="aff11-07067437221145013" ref-type="aff">11</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lim</surname>
                    <given-names>Ron</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff12-07067437221145013" ref-type="aff">12</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hassan</surname>
                    <given-names>Ahmed N.</given-names>
                  </name>
                  <degrees>MD, MPH</degrees>
                  <xref rid="aff6-07067437221145013" ref-type="aff">6</xref>
                  <xref rid="aff7-07067437221145013" ref-type="aff">7</xref>
                  <xref rid="aff9-07067437221145013" ref-type="aff">9</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Brissette</surname>
                    <given-names>Suzanne</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff2-07067437221145013" ref-type="aff">2</xref>
                  <xref rid="aff13-07067437221145013" ref-type="aff">13</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Marsan</surname>
                    <given-names>Stéphanie</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff2-07067437221145013" ref-type="aff">2</xref>
                  <xref rid="aff13-07067437221145013" ref-type="aff">13</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Talbot</surname>
                    <given-names>Annie</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff2-07067437221145013" ref-type="aff">2</xref>
                  <xref rid="aff13-07067437221145013" ref-type="aff">13</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8474-508X</contrib-id>
                  <name>
                    <surname>Jutras-Aswad</surname>
                    <given-names>Didier</given-names>
                  </name>
                  <degrees>MD, MSc</degrees>
                  <xref rid="aff1-07067437221145013" ref-type="aff">1</xref>
                  <xref rid="aff2-07067437221145013" ref-type="aff">2</xref>
                  <xref rid="corresp1-07067437221145013" ref-type="corresp"/>
                </contrib>
                <contrib contrib-type="author">
                  <collab>for the OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse</collab>
                </contrib>
              </contrib-group>
              <aff id="aff1-07067437221145013"><label>1</label>Department of Psychiatry and Addictology, Faculty of Medicine, <institution-wrap><institution-id institution-id-type="Ringgold">5622</institution-id><institution content-type="university">Université de Montréal</institution></institution-wrap>, Montréal, Québec, Canada</aff>
              <aff id="aff2-07067437221145013"><label>2</label>Research Centre, <institution-wrap><institution-id institution-id-type="Ringgold">25443</institution-id><institution content-type="university">Centre Hospitalier de l’Université de Montréal (CRCHUM)</institution></institution-wrap>, Montréal, Québec, Canada</aff>
              <aff id="aff3-07067437221145013"><label>3</label>Unité de recherche clinique appliquée, <institution-wrap><institution-id institution-id-type="Ringgold">25461</institution-id><institution content-type="university">Centre hospitalier universitaire Ste-Justine</institution></institution-wrap>, Montréal, Québec, Canada</aff>
              <aff id="aff4-07067437221145013"><label>4</label><institution-wrap><institution-id institution-id-type="Ringgold">558158</institution-id><institution content-type="university">British Columbia Centre on Substance Use</institution></institution-wrap>, Vancouver, British Columbia, Canada</aff>
              <aff id="aff5-07067437221145013"><label>5</label>Department of Medicine, Faculty of Medicine, <institution-wrap><institution-id institution-id-type="Ringgold">8166</institution-id><institution content-type="university">University of British Columbia</institution></institution-wrap>, Vancouver, British Columbia, Canada</aff>
              <aff id="aff6-07067437221145013"><label>6</label>Translational Addiction Research Laboratory, Campbell Family Mental Health Research Institute, Center for Addiction and Mental Health, Toronto, Ontario, Canada</aff>
              <aff id="aff7-07067437221145013"><label>7</label>Department of Pharmacology and Toxicology, Faculty of Medicine, <institution-wrap><institution-id institution-id-type="Ringgold">7938</institution-id><institution content-type="university">University of Toronto</institution></institution-wrap>, Toronto, Ontario, Canada</aff>
              <aff id="aff8-07067437221145013"><label>8</label>Department of Family and Community Medicine, Faculty of Medicine, <institution-wrap><institution-id institution-id-type="Ringgold">7938</institution-id><institution content-type="university">University of Toronto</institution></institution-wrap>, Toronto, Ontario, Canada</aff>
              <aff id="aff9-07067437221145013"><label>9</label>Department of Psychiatry, <institution-wrap><institution-id institution-id-type="Ringgold">7938</institution-id><institution content-type="university">University of Toronto</institution></institution-wrap>, Toronto, Ontario, Canada</aff>
              <aff id="aff10-07067437221145013"><label>10</label>Dalla Lana School of Public Health, <institution-wrap><institution-id institution-id-type="Ringgold">7938</institution-id><institution content-type="university">University of Toronto</institution></institution-wrap>, Toronto, Ontario, Canada</aff>
              <aff id="aff11-07067437221145013"><label>11</label><institution-wrap><institution-id institution-id-type="Ringgold">585687</institution-id><institution content-type="university">Waypoint Research Institute</institution></institution-wrap>, Waypoint Centre for Mental Health Care, Penetanguishene, Ontario, Canada</aff>
              <aff id="aff12-07067437221145013"><label>12</label>Department of Medicine and Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada</aff>
              <aff id="aff13-07067437221145013"><label>13</label>Department of Family and Emergency Medicine, Faculty of Medicine, <institution-wrap><institution-id institution-id-type="Ringgold">5622</institution-id><institution content-type="university">Université de Montréal</institution></institution-wrap>, Montréal, Québec, Canada</aff>
              <author-notes>
                <corresp id="corresp1-07067437221145013">Didier Jutras-Aswad, MD, MSc, Research Centre, Centre hospitalier de l’Université de Montréal, 900 St-Denis Street, 5th Floor, Room R05.746, Montreal, Quebec, Canada H2X 1P1. 
Email: <email>didier.jutras-aswad@umontreal.ca</email>
</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>14</day>
                <month>12</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>8</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>14</day>
                <month>12</month>
                <year>2022</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>68</volume>
              <issue>8</issue>
              <fpage>572</fpage>
              <lpage>585</lpage>
              <permissions>
                <copyright-statement>© The Author(s) 2022</copyright-statement>
                <copyright-year>2022</copyright-year>
                <copyright-holder content-type="sage">Canadian Psychiatric Association</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p>
                </license>
              </permissions>
              <abstract>
                <sec>
                  <title>Objective</title>
                  <p>This study aimed to evaluate the effectiveness of flexible take-home dosing of buprenorphine/naloxone (BUP/NX) and methadone standard model of care in reducing depressive symptoms in people with prescription-type opioid use disorder (POUD). This trial also evaluated whether improvements in depressive symptoms were mediated by opioid use.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p>Analyzed data came from the OPTIMA study (clinicaltrials.gov identifier: NCT03033732), a pragmatic randomised controlled trial comparing flexible take-home dosing of BUP/NX and methadone standard model of care for reducing opioid use in people with POUD. A total of 272 participants were recruited in four Canadian provinces. Participants were randomised 1:1 to BUP/NX or methadone. After treatment induction, past two-week opioid use was measured using the Timeline Followback every two weeks for a total of 24 weeks. Depressive symptoms were measured with the Beck Depression Inventory at baseline, weeks 12 and 24.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p>Both BUP/NX and methadone significantly reduced depressive symptoms at week 12 (aβ ± SE = −3.167 ± 1.233; <italic toggle="yes">P</italic> &lt; 0.001) and week 24 (aβ ± SE = −7.280 ± 1.285; <italic toggle="yes">P</italic> &lt; 0.001), with no interaction between type of treatment and time (<italic toggle="yes">P</italic> = 0.284). Improvements in depressive symptoms were only partially mediated by a reduction in opioid use (proportion mediated = 36.8%; 95% confidence interval = −1.158 to −0.070; <italic toggle="yes">P</italic> = 0.015).</p>
                </sec>
                <sec>
                  <title>Conclusions</title>
                  <p>BUP/NX and methadone showed similar effectiveness in decreasing comorbid depressive symptoms in people with POUD. This effect was partially explained by a reduction in opioid use. As both treatments seem equally effective, clinicians are encouraged to tailor the selection of OAT to patients’ needs and characteristics.</p>
                </sec>
              </abstract>
              <trans-abstract abstract-type="normal" xml:lang="fr">
                <title>Abrégé</title>
                <sec>
                  <title>Objectif</title>
                  <p>La présente étude visait à évaluer l’efficacité d'une approche flexible de doses à emporter à domicile de buprénorphine/naloxone (BUP/NX) et du modèle de soins standard avec la méthadone pour réduire les symptômes dépressifs chez les personnes vivant avec un trouble lié à l’utilisation d’opioïdes de prescription (TUOP). Le présent essai a également évalué si les améliorations des symptômes dépressifs étaient médiées par l’utilisation d’opioïdes.</p>
                </sec>
                <sec>
                  <title>Méthodes</title>
                  <p>Les données analysées provenaient de l’étude OPTIMA (identifiant clinicaltrials.gov : NCT03033732), un essai randomisé contrôlé pragmatique comparant l'usage flexible de dosesà emporter à domicile de BUP/NX et le modèle de soins standard avec la méthadone pour réduire la consommation d’opioïdes chez les personnes ayant un TUOP. Un total de 272 participants a été recruté dans quatre provinces canadiennes. Les participants ont été randomisés 1:1 à lau BUP/NX ou à la méthadone. Après l'induction du traitement, l’utilisation d’opioïdes dans les deux dernières semaines a été mesurée à l’aide du Timeline Followback à toutes les deux semaines pendant 24 semaines. Les symptômes dépressifs étaient mesurés à l’aide de l’Inventaire de dépression de Beck au début de l'étude et aux semaines 12 et 24.</p>
                </sec>
                <sec>
                  <title>Résultats</title>
                  <p>La BUP/NX et la méthadone réduisaient significativement toutes deux les symptômes dépressifs à la 12<sup>e</sup> semaine (aβ ± SE = -3,167 ± 1,233; p,&lt;,0,001) et à la 24<sup>e</sup> semaine (aβ ± SE = -7,280 ± 1,285; p &lt; 0,001), sans interaction entre le type de traitement et le temps (p = 0,284). Les améliorations des symptômes dépressifs n’étaient que partiellement médiées par une réduction de l’utilisation d’opioïdes (proportion médiée= 36,8%; IC à 95% 1,158 à −0,070; p = 0,015).</p>
                </sec>
                <sec>
                  <title>Conclusions</title>
                  <p>La BUP/NX et la méthadone ont démontré une efficacité semblable à réduire les symptômes dépressifs comorbides chez des personnes ayant un TUOP. Cet effet s’expliquait partiellement par une réduction de l’utilisation d’opioïdes. Comme les deux traitements semblent similairement efficaces, les cliniciens sont encouragés d’adapter la sélection du traitement agoniste opioïde aux besoins et aux caractéristiques des patients.</p>
                </sec>
              </trans-abstract>
              <kwd-group>
                <kwd>comorbidity</kwd>
                <kwd>depressive disorders</kwd>
                <kwd>dual diagnosis</kwd>
                <kwd>major depressive disorder</kwd>
                <kwd>randomised controlled trial</kwd>
                <kwd>substance use disorders</kwd>
              </kwd-group>
              <funding-group specific-use="FundRef">
                <award-group id="award1-07067437221145013">
                  <funding-source id="funding1-07067437221145013">
                    <institution-wrap>
                      <institution>Health Canada</institution>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100000008</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="award2-07067437221145013">
                  <funding-source id="funding2-07067437221145013">
                    <institution-wrap>
                      <institution>Institute of Neurosciences, Mental Health and Addiction</institution>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100000034</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id rid="funding2-07067437221145013">SMN-139148</award-id>
                  <award-id rid="funding2-07067437221145013">SMN-139149</award-id>
                  <award-id rid="funding2-07067437221145013">SMN-139150</award-id>
                  <award-id rid="funding2-07067437221145013">SMN-139151</award-id>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>typesetter</meta-name>
                  <meta-value>ts19</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="section1-07067437221145013">
              <title>Introduction</title>
              <p>Between 47 and 60 million individuals use opioids for nonmedical reasons, with the highest rate being in North America.<sup><xref rid="bibr1-07067437221145013" ref-type="bibr">1</xref>,<xref rid="bibr2-07067437221145013" ref-type="bibr">2</xref></sup> Among people with prescription-type opioid use disorder (POUD), depression is the most common psychiatric comorbidity, with an estimated current prevalence between 9% and 61%.<sup><xref rid="bibr3-07067437221145013" ref-type="bibr">3</xref>,<xref rid="bibr4-07067437221145013" ref-type="bibr">4</xref></sup> Opioid use disorder is also associated with an increased risk of developing subsequent depression that persists for decades.<sup><xref rid="bibr5-07067437221145013" ref-type="bibr">5</xref></sup> Traditional treatments for depression are challenging to implement in OUD populations. Indeed, pharmacological interactions between some antidepressants and OATs can lead to reduced bioavailability and effectiveness<sup><xref rid="bibr6-07067437221145013" ref-type="bibr">6</xref>,<xref rid="bibr7-07067437221145013" ref-type="bibr">7</xref></sup> and increased cardiotoxicity.<sup><xref rid="bibr8-07067437221145013" ref-type="bibr">8</xref></sup> Moreover, there is only a little evidence of antidepressants effectiveness in people with OUD as these populations have classically been excluded from such trials. Psychotherapy may also be difficult to deliver to people with OUD, as they often experience unstable living conditions, cognitive impairments, or limited financial resources.<sup><xref rid="bibr9-07067437221145013" ref-type="bibr">9</xref></sup></p>
              <p>Two OATs – buprenorphine/naloxone (BUP/NX) and methadone – have shown beneficial impacts on depressive symptomatology. BUP/NX can significantly improve depressive symptoms, independently of drug use, or withdrawal symptoms.<sup><xref rid="bibr10-07067437221145013" ref-type="bibr">10</xref>,<xref rid="bibr17-07067437221145013" ref-type="bibr">17</xref></sup> A recent open-label clinical trial evaluating BUP/NX for treatment-resistant depression in people with opioid use disorder (OUD) reported a significant reduction in depressive mood 48 h after BUP/NX initiation.<sup><xref rid="bibr18-07067437221145013" ref-type="bibr">18</xref></sup> Karp and colleagues also found a significant decline in depression severity during BUP/NX treatment and a sudden increase when treatment was discontinued.<sup><xref rid="bibr19-07067437221145013" ref-type="bibr">1</xref></sup></p>
              <p>Methadone may also improve depressive symptoms, although studies are relatively limited. In a randomised controlled trial comparing methadone in combination with fluoxetine to methadone alone, both treatment arms significantly reduced depressive symptoms compared to baseline.<sup><xref rid="bibr20-07067437221145013" ref-type="bibr">20</xref></sup> Improvements were unrelated to drug use, and the addition of fluoxetine did not confer additional improvements.<sup><xref rid="bibr20-07067437221145013" ref-type="bibr">20</xref></sup> Another study found that methadone can quickly alleviate depressive states associated with opioid withdrawal.<sup><xref rid="bibr21-07067437221145013" ref-type="bibr">21</xref></sup> A recent meta-analysis on the effect of methadone on depression among people with OUD found significant reductions in depressive symptoms following methadone initiation.<sup><xref rid="bibr22-07067437221145013" ref-type="bibr">22</xref></sup></p>
              <p>BUP/NX is thought to have a superior antidepressant profile than methadone due to its antagonist action on kappa opioid receptors.<sup><xref rid="bibr10-07067437221145013" ref-type="bibr">10</xref>,<xref rid="bibr15-07067437221145013" ref-type="bibr">15</xref>,<xref rid="bibr18-07067437221145013" ref-type="bibr">18</xref>,<xref rid="bibr23-07067437221145013" ref-type="bibr">23</xref></sup> BUP/NX also interacts with serotoninergic and hypothalamic–pituitary–adrenal systems,<sup><xref rid="bibr10-07067437221145013" ref-type="bibr">10</xref>,<xref rid="bibr19-07067437221145013" ref-type="bibr">19</xref></sup> two systems involved in the pathogenesis and maintenance of depression. To our knowledge, the only study that compared the effectiveness of methadone and buprenorphine (without naloxone) in decreasing depressive symptoms found that both treatments improved depression in heroin-dependent subjects. Baseline depressive symptoms and treatment retention were predictive of symptoms at three months for participants receiving methadone but not for those receiving buprenorphine. These results show that buprenorphine can effectively alleviate depressive symptoms regardless of depression severity and may have a longer term effect. Therefore, although study conclusions were limited by its small sample size, the authors hypothesised that buprenorphine might have a differential impact on depressive symptoms and recommended further trials to evaluate this hypothesis.<sup><xref rid="bibr24-07067437221145013" ref-type="bibr">24</xref></sup></p>
              <p>Since this latter study published in 2004, no recent data have been published on the antidepressant properties of OATs in people treated for OUD. However, trends in opioid use have changed drastically since the 2000s, switching from mainly heroin use to higher potency prescription opioids.<sup><xref rid="bibr25-07067437221145013" ref-type="bibr">25</xref></sup> Indeed, from 1999 to 2011, prescription opioid misuse increased between two- and five-fold.<sup><xref rid="bibr26-07067437221145013" ref-type="bibr">26</xref></sup> It remains unclear whether studies conducted in samples with heroin use disorder can be extrapolated to POUD populations.</p>
              <p>Considering that depression is highly prevalent in people with POUD, and that depression has been reported to be the strongest predictor of OATs outcomes,<sup><xref rid="bibr27-07067437221145013" ref-type="bibr">27</xref></sup> new robust data on the antidepressant properties of OATs in POUD are urgently needed.</p>
              <p>This secondary analysis evaluated the differential effectiveness of BUP/NX and methadone models of care in decreasing depressive symptomatology in Canadians with POUD. We further investigated whether decreases in depressive symptoms were mediated by the number of days of opioid use in the past two weeks. We hypothesised that flexible take-home dosing of BUP/NX would be superior to the methadone standard model of care in decreasing depressive symptomatology.</p>
            </sec>
            <sec sec-type="methods" id="section2-07067437221145013">
              <title>Methods</title>
              <sec id="section2A-07067437221145013">
                <title>Study Design</title>
                <p>Our study is a secondary analysis of data drawn from the OPTIMA study, a pan-Canadian, two-arm, open-label, multicentric, pragmatic randomised controlled trial designed to compare flexible take-home dosing of BUP/NX to the methadone standard model of care in treating POUD. OPTIMA's methodology and main outcomes have been published in detail elsewhere.<sup><xref rid="bibr28-07067437221145013" ref-type="bibr">28</xref>,<xref rid="bibr29-07067437221145013" ref-type="bibr">29</xref></sup> This study was conducted in full conformity with the international Good Clinical Practice guidelines from the International Conference on Harmonisation (Declaration of Helsinki), Canadian (Tri-Council Policy Statement, Health Canada division 5), provincial, and institutional guidelines. All study sites’ institutional ethics review boards have approved this study, and all participants signed an informed consent after study procedures had been fully explained. The secondary analysis plan was not registered and has not been reviewed by ethics review boards, other than through the approval of the main trial.</p>
              </sec>
              <sec id="section2B-07067437221145013">
                <title>Participants</title>
                <p>A total of 272 participants were randomised. The main inclusion criteria were being aged between 18 and 64 years, having a POUD diagnosis (DSM-5 criteria), and being of non-childbearing potential or using contraception. Exclusion criteria included having any preexisting physiological or severe psychiatric conditions or using medication precluding safe participation, self-reporting using heroin as the most frequent opioid in the 30 days prior to enrollment, currently receiving OAT, having pain requiring opioid treatment, having a pending legal action preventing study completion, or being pregnant, breastfeeding, or planning to conceive during the study period. We excluded from analyses participants who did not provide any BDI-II data throughout the study.</p>
              </sec>
              <sec id="section2C-07067437221145013">
                <title>Procedures</title>
                <p>This study was led by the Canadian Research Initiative in Substance Misuse (CRISM) at the following sites: The Rapid Access Addiction Clinic (Vancouver, BC); the Portland Hotel Society Clinic (Vancouver, BC); the Opioid Dependency Program Clinic (Edmonton, AB); the Opioid Dependency Program Clinic (Calgary, AB); the Centre for Addiction and Mental Health (Toronto, ON); the Ontario Addiction Treatment Centre (Sudbury, ON); the Centre hospitalier de l’Université de Montréal (Montréal, QC); and the Centre de Recherche et d’Aide pour Narcomane (Montréal, QC). Eligible participants completed baseline assessments and were randomised in a 1:1 ratio to receive methadone or BUP/NX. Assigned OAT was initiated in accordance with local guidelines and Health Canada-approved product monographs. Follow-up visits took place every two weeks during which questionnaires were administered and urine samples were collected. Participants received a $40 compensation after each study visit, for a maximum of $560. For more details on procedures, refer to our previous publication.<sup><xref rid="bibr28-07067437221145013" ref-type="bibr">28</xref>,<xref rid="bibr29-07067437221145013" ref-type="bibr">29</xref></sup></p>
              </sec>
              <sec id="section2D-07067437221145013">
                <title>Measurements</title>
                <p>Our main outcome was depressive symptoms, as measured by the Beck Depression Inventory – Second Version (BDI-II) at baseline, week 12, and week 24. The BDI-II questionnaire consists of 21 self-reported items resulting in a total score between 0 and 63, with higher scores representing more severe symptomatology. Opioid use was quantified using the Timeline Follow-Back (TLFB) every two weeks for the 24-week trial duration. For these analyses, we only included days of opioid use in the past two weeks prior to baseline, week 12, and week 24 visits.</p>
              </sec>
            </sec>
            <sec id="section3-07067437221145013">
              <title>Statistical Analyses</title>
              <sec id="section3A-07067437221145013">
                <title>Primary Analyses</title>
                <p>We used a repeated measure generalised linear model (rmGLM) to estimate the impact of OAT group on depressive symptoms using the <italic toggle="yes">lme4</italic> package.<sup><xref rid="bibr30-07067437221145013" ref-type="bibr">30</xref></sup> We adjusted our model for the study site and lifetime heroin use. A treatment*time interaction term was added to assess the differential impact of OAT across time. To measure differences between visits, we calculated contrasts with Tukey's method of adjustments for multiple comparisons. Analyses were performed using R v4.0.3 (R Core Team) assuming a two-tailed 5% significance level.</p>
              </sec>
              <sec id="section3B-07067437221145013">
                <title>Post-hoc Analyses</title>
                <p>We conducted <italic toggle="yes">post-hoc</italic> mediation analyses to estimate the direct and indirect effects of the number of weeks taking OAT on depressive symptoms using the <italic toggle="yes">mediation</italic> package and 10,000 iterations.<sup><xref rid="bibr31-07067437221145013" ref-type="bibr">31</xref></sup> Days of opioid use were treated as a within-subject mediator. We also performed subgroup analyses to evaluate whether the mediation effect was similar in both groups.</p>
              </sec>
              <sec id="section3C-07067437221145013">
                <title>Handling of Missing Data</title>
                <p>Main analyses were performed using collected data only. Participants with incomplete observations for the BDI-II (e.g., did not answer item 15) were considered as missing for this time point. For <italic toggle="yes">post-hoc</italic> mediation analyses, missing values of days of opioid use were imputed with baseline data. For depressive scores, we carried the last available information forward.</p>
              </sec>
              <sec id="section3D-07067437221145013">
                <title>Sensitivity Analyses</title>
                <p>We performed per-protocol sensitivity analyses including 1) participants initiating the assigned treatment and 2) participants still actively in the study and having a positive urine drug screening to the assigned treatment at week 24 (i.e., retained participants). Given that recruitment and data collection were impacted by the COVID-19 pandemic, we also performed sensitivity analyses removing data collected after March 24, 2020.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="section4-07067437221145013">
              <title>Results</title>
              <sec id="section4A-07067437221145013">
                <title>Participants</title>
                <p><xref rid="fig1-07067437221145013" ref-type="fig">Figure 1</xref> shows the CONSORT flow diagram (modified from Jutras-Aswad et al.<sup><xref rid="bibr29-07067437221145013" ref-type="bibr">29</xref></sup>). A total of 272 eligible participants were randomised to methadone (<italic toggle="yes">n</italic> = 134, 49.3%) or BUP/NX (<italic toggle="yes">n</italic> = 138, 50.7%). Eleven participants (methadone, <italic toggle="yes">n</italic> = 8; BUP/NX, <italic toggle="yes">n</italic> = 3) did not provide any BDI-II data and were, therefore, excluded from the analyses. One participant was excluded due to death before data collection. Sample characteristics are presented in <xref rid="table1-07067437221145013" ref-type="table">Table 1</xref>. Briefly, most participants were middle-aged (mean ± standard deviation [SD] = 39.9 ± 10.9), never married (<italic toggle="yes">n</italic> = 171, 65.8%), white, (<italic toggle="yes">n</italic> = 175, 67.3%), men (<italic toggle="yes">n</italic> = 168, 64.6%), and had used heroin at least once in their lifetime (<italic toggle="yes">n</italic> = 176, 67.7%). About a third (<italic toggle="yes">n</italic> = 80, 30.8%) of our sample reported having very unstable housing, while a quarter (<italic toggle="yes">n</italic> = 70, 26.9%) reported very stable housing. High school was the highest level of schooling completed for 112 (43.1%) participants, while 45 (17.3%) participants had not completed high school. At baseline, participants in the methadone group used on average (±SD) of 12.3 (±3.7) days in the past two weeks. Participants from the BUP/NX group had similar use with 12.1 (±3.9) days of opioid use.</p>
                <fig position="float" id="fig1-07067437221145013">
                  <label>Figure 1.</label>
                  <caption>
                    <p>CONSORT flow diagram illustrating pre-screening, screening, randomising, and analysis with the number of participants for each step. *Thirteen participants were screened twice but are counted only once in the flowchart. **Other reasons for exclusions were unspecified (<italic toggle="yes">n</italic> = 14), incomplete screening (<italic toggle="yes">n</italic> = 4), failure to complete baseline visit within a 28-day time window (<italic toggle="yes">n</italic> = 3), and incarceration (<italic toggle="yes">n</italic> = 1). ***One participant attempted suicide and withdrew consent six days later. BDI-II, Beck Depression Inventory – Second Edition; BUP/NX, buprenorphine/naloxone; COVID-19, coronavirus disease 2019; <italic toggle="yes">n</italic>, number of participants; OAT, opioid agonist treatment; POUD, prescription opioid use disorder; SAE, serious adverse events.</p>
                  </caption>
                  <graphic xlink:href="10.1177_07067437221145013-fig1" position="float"/>
                </fig>
                <table-wrap position="float" id="table1-07067437221145013">
                  <label>Table 1.</label>
                  <caption>
                    <p>Demographic and Characteristics of Analyzed Participants.</p>
                  </caption>
                  <alternatives>
                    <graphic xlink:href="10.1177_07067437221145013-table1" position="float"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" span="1"/>
                        <col align="left" span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" colspan="2" rowspan="2">Characteristics</th>
                          <th align="center" colspan="4" rowspan="1">Treatment group</th>
                          <th align="center" rowspan="1" colspan="1"/>
                          <th align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <th align="center" colspan="2" rowspan="1">BUP/NX (<italic toggle="yes">n</italic> = 135)</th>
                          <th align="center" colspan="2" rowspan="1">Methadone 
(<italic toggle="yes">n</italic> = 125)</th>
                          <th align="left" colspan="2" rowspan="1">Total (<italic toggle="yes">n</italic> = 260)</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td colspan="2" rowspan="1">Age, mean (SD), years</td>
                          <td rowspan="1" colspan="1">38.8</td>
                          <td rowspan="1" colspan="1">10.7</td>
                          <td rowspan="1" colspan="1">39.2</td>
                          <td rowspan="1" colspan="1">10.3</td>
                          <td rowspan="1" colspan="1">39.0</td>
                          <td rowspan="1" colspan="1">1.5</td>
                        </tr>
                        <tr>
                          <td colspan="2" rowspan="1">Female sex, <italic toggle="yes">n</italic> (%)</td>
                          <td rowspan="1" colspan="1">43</td>
                          <td rowspan="1" colspan="1">31.9</td>
                          <td rowspan="1" colspan="1">46</td>
                          <td rowspan="1" colspan="1">36.8</td>
                          <td rowspan="1" colspan="1">89</td>
                          <td rowspan="1" colspan="1">34.2</td>
                        </tr>
                        <tr>
                          <td colspan="2" rowspan="1">Gender, <italic toggle="yes">n</italic> (%)</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Man</td>
                          <td rowspan="1" colspan="1">90</td>
                          <td rowspan="1" colspan="1">66.7</td>
                          <td rowspan="1" colspan="1">78</td>
                          <td rowspan="1" colspan="1">62.4</td>
                          <td rowspan="1" colspan="1">168</td>
                          <td rowspan="1" colspan="1">64.6</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Woman</td>
                          <td rowspan="1" colspan="1">44</td>
                          <td rowspan="1" colspan="1">32.6</td>
                          <td rowspan="1" colspan="1">46</td>
                          <td rowspan="1" colspan="1">36.8</td>
                          <td rowspan="1" colspan="1">90</td>
                          <td rowspan="1" colspan="1">34.6</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Transgender</td>
                          <td rowspan="1" colspan="1">1</td>
                          <td rowspan="1" colspan="1">0.7</td>
                          <td rowspan="1" colspan="1">1</td>
                          <td rowspan="1" colspan="1">0.8</td>
                          <td rowspan="1" colspan="1">2</td>
                          <td rowspan="1" colspan="1">0.8</td>
                        </tr>
                        <tr>
                          <td colspan="2" rowspan="1">Prescription drug coverage, <italic toggle="yes">n</italic> (%)</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Provincial health insurance</td>
                          <td rowspan="1" colspan="1">39</td>
                          <td rowspan="1" colspan="1">28.9</td>
                          <td rowspan="1" colspan="1">36</td>
                          <td rowspan="1" colspan="1">28.8</td>
                          <td rowspan="1" colspan="1">75</td>
                          <td rowspan="1" colspan="1">28.8</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Pharmacare</td>
                          <td rowspan="1" colspan="1">21</td>
                          <td rowspan="1" colspan="1">15.6</td>
                          <td rowspan="1" colspan="1">12</td>
                          <td rowspan="1" colspan="1">9.6</td>
                          <td rowspan="1" colspan="1">33</td>
                          <td rowspan="1" colspan="1">12.7</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Persons with disabilities</td>
                          <td rowspan="1" colspan="1">8</td>
                          <td rowspan="1" colspan="1">5.9</td>
                          <td rowspan="1" colspan="1">15</td>
                          <td rowspan="1" colspan="1">12.0</td>
                          <td rowspan="1" colspan="1">23</td>
                          <td rowspan="1" colspan="1">8.9</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Private insurance</td>
                          <td rowspan="1" colspan="1">6</td>
                          <td rowspan="1" colspan="1">4.4</td>
                          <td rowspan="1" colspan="1">7</td>
                          <td rowspan="1" colspan="1">5.6</td>
                          <td rowspan="1" colspan="1">13</td>
                          <td rowspan="1" colspan="1">5.0</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Other</td>
                          <td rowspan="1" colspan="1">35</td>
                          <td rowspan="1" colspan="1">25.9</td>
                          <td rowspan="1" colspan="1">29</td>
                          <td rowspan="1" colspan="1">23.2</td>
                          <td rowspan="1" colspan="1">64</td>
                          <td rowspan="1" colspan="1">24.6</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">No coverage</td>
                          <td rowspan="1" colspan="1">24</td>
                          <td rowspan="1" colspan="1">17.8</td>
                          <td rowspan="1" colspan="1">22</td>
                          <td rowspan="1" colspan="1">17.6</td>
                          <td rowspan="1" colspan="1">46</td>
                          <td rowspan="1" colspan="1">17.7</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Unknown</td>
                          <td rowspan="1" colspan="1">2</td>
                          <td rowspan="1" colspan="1">1.5</td>
                          <td rowspan="1" colspan="1">4</td>
                          <td rowspan="1" colspan="1">3.2</td>
                          <td rowspan="1" colspan="1">6</td>
                          <td rowspan="1" colspan="1">2.3</td>
                        </tr>
                        <tr>
                          <td colspan="2" rowspan="1">Lifetime heroin use, <italic toggle="yes">n</italic> (%)</td>
                          <td rowspan="1" colspan="1">93</td>
                          <td rowspan="1" colspan="1">68.9</td>
                          <td rowspan="1" colspan="1">83</td>
                          <td rowspan="1" colspan="1">66.4</td>
                          <td rowspan="1" colspan="1">176</td>
                          <td rowspan="1" colspan="1">67.7</td>
                        </tr>
                        <tr>
                          <td colspan="2" rowspan="1">Highest level of schooling completed, <italic toggle="yes">n</italic> (%)</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Incomplete high school</td>
                          <td rowspan="1" colspan="1">17</td>
                          <td rowspan="1" colspan="1">12.6</td>
                          <td rowspan="1" colspan="1">28</td>
                          <td rowspan="1" colspan="1">22.4</td>
                          <td rowspan="1" colspan="1">45</td>
                          <td rowspan="1" colspan="1">17.3</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">High school</td>
                          <td rowspan="1" colspan="1">66</td>
                          <td rowspan="1" colspan="1">48.9</td>
                          <td rowspan="1" colspan="1">46</td>
                          <td rowspan="1" colspan="1">36.8</td>
                          <td rowspan="1" colspan="1">112</td>
                          <td rowspan="1" colspan="1">43.1</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Technical/trade school</td>
                          <td rowspan="1" colspan="1">14</td>
                          <td rowspan="1" colspan="1">10.4</td>
                          <td rowspan="1" colspan="1">11</td>
                          <td rowspan="1" colspan="1">8.8</td>
                          <td rowspan="1" colspan="1">25</td>
                          <td rowspan="1" colspan="1">9.6</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Some college/university</td>
                          <td rowspan="1" colspan="1">15</td>
                          <td rowspan="1" colspan="1">11.1</td>
                          <td rowspan="1" colspan="1">16</td>
                          <td rowspan="1" colspan="1">12.8</td>
                          <td rowspan="1" colspan="1">31</td>
                          <td rowspan="1" colspan="1">11.9</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">College/university</td>
                          <td rowspan="1" colspan="1">23</td>
                          <td rowspan="1" colspan="1">17.0</td>
                          <td rowspan="1" colspan="1">23</td>
                          <td rowspan="1" colspan="1">18.4</td>
                          <td rowspan="1" colspan="1">46</td>
                          <td rowspan="1" colspan="1">17.7</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Choose not to answer</td>
                          <td rowspan="1" colspan="1">0</td>
                          <td rowspan="1" colspan="1">0.0</td>
                          <td rowspan="1" colspan="1">1</td>
                          <td rowspan="1" colspan="1">0.8</td>
                          <td rowspan="1" colspan="1">1</td>
                          <td rowspan="1" colspan="1">0.4</td>
                        </tr>
                        <tr>
                          <td colspan="2" rowspan="1">Ethnicity, <italic toggle="yes">n</italic> (%)</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">White</td>
                          <td rowspan="1" colspan="1">92</td>
                          <td rowspan="1" colspan="1">68.1</td>
                          <td rowspan="1" colspan="1">83</td>
                          <td rowspan="1" colspan="1">66.4</td>
                          <td rowspan="1" colspan="1">175</td>
                          <td rowspan="1" colspan="1">67.3</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Asian</td>
                          <td rowspan="1" colspan="1">3</td>
                          <td rowspan="1" colspan="1">2.2</td>
                          <td rowspan="1" colspan="1">1</td>
                          <td rowspan="1" colspan="1">0.8</td>
                          <td rowspan="1" colspan="1">4</td>
                          <td rowspan="1" colspan="1">1.5</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Latin American/Hispanic</td>
                          <td rowspan="1" colspan="1">1</td>
                          <td rowspan="1" colspan="1">0.7</td>
                          <td rowspan="1" colspan="1">0</td>
                          <td rowspan="1" colspan="1">0.0</td>
                          <td rowspan="1" colspan="1">1</td>
                          <td rowspan="1" colspan="1">0.4</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Middle Eastern</td>
                          <td rowspan="1" colspan="1">1</td>
                          <td rowspan="1" colspan="1">0.7</td>
                          <td rowspan="1" colspan="1">1</td>
                          <td rowspan="1" colspan="1">0.8</td>
                          <td rowspan="1" colspan="1">2</td>
                          <td rowspan="1" colspan="1">0.8</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Black African</td>
                          <td rowspan="1" colspan="1">0</td>
                          <td rowspan="1" colspan="1">0.0</td>
                          <td rowspan="1" colspan="1">2</td>
                          <td rowspan="1" colspan="1">1.6</td>
                          <td rowspan="1" colspan="1">2</td>
                          <td rowspan="1" colspan="1">0.8</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Black Caribbean</td>
                          <td rowspan="1" colspan="1">2</td>
                          <td rowspan="1" colspan="1">1.5</td>
                          <td rowspan="1" colspan="1">0</td>
                          <td rowspan="1" colspan="1">0.0</td>
                          <td rowspan="1" colspan="1">2</td>
                          <td rowspan="1" colspan="1">0.8</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">First Nations</td>
                          <td rowspan="1" colspan="1">23</td>
                          <td rowspan="1" colspan="1">17.0</td>
                          <td rowspan="1" colspan="1">19</td>
                          <td rowspan="1" colspan="1">15.2</td>
                          <td rowspan="1" colspan="1">42</td>
                          <td rowspan="1" colspan="1">16.2</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Metis</td>
                          <td rowspan="1" colspan="1">7</td>
                          <td rowspan="1" colspan="1">5.2</td>
                          <td rowspan="1" colspan="1">6</td>
                          <td rowspan="1" colspan="1">4.8</td>
                          <td rowspan="1" colspan="1">13</td>
                          <td rowspan="1" colspan="1">5.0</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Other</td>
                          <td rowspan="1" colspan="1">5</td>
                          <td rowspan="1" colspan="1">3.7</td>
                          <td rowspan="1" colspan="1">11</td>
                          <td rowspan="1" colspan="1">8.8</td>
                          <td rowspan="1" colspan="1">16</td>
                          <td rowspan="1" colspan="1">6.2</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Choose not to answer</td>
                          <td rowspan="1" colspan="1">1</td>
                          <td rowspan="1" colspan="1">0.7</td>
                          <td rowspan="1" colspan="1">2</td>
                          <td rowspan="1" colspan="1">1.6</td>
                          <td rowspan="1" colspan="1">3</td>
                          <td rowspan="1" colspan="1">1.2</td>
                        </tr>
                        <tr>
                          <td colspan="2" rowspan="1">Current living situation, <italic toggle="yes">n</italic> (%)</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Very unstable</td>
                          <td rowspan="1" colspan="1">38</td>
                          <td rowspan="1" colspan="1">28.1</td>
                          <td rowspan="1" colspan="1">42</td>
                          <td rowspan="1" colspan="1">33.6</td>
                          <td rowspan="1" colspan="1">80</td>
                          <td rowspan="1" colspan="1">30.8</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">A little unstable</td>
                          <td rowspan="1" colspan="1">21</td>
                          <td rowspan="1" colspan="1">15.6</td>
                          <td rowspan="1" colspan="1">18</td>
                          <td rowspan="1" colspan="1">14.4</td>
                          <td rowspan="1" colspan="1">39</td>
                          <td rowspan="1" colspan="1">15.0</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Neither unstable nor stable</td>
                          <td rowspan="1" colspan="1">9</td>
                          <td rowspan="1" colspan="1">6.7</td>
                          <td rowspan="1" colspan="1">13</td>
                          <td rowspan="1" colspan="1">10.4</td>
                          <td rowspan="1" colspan="1">22</td>
                          <td rowspan="1" colspan="1">8.5</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">A little stable</td>
                          <td rowspan="1" colspan="1">24</td>
                          <td rowspan="1" colspan="1">17.8</td>
                          <td rowspan="1" colspan="1">17</td>
                          <td rowspan="1" colspan="1">13.6</td>
                          <td rowspan="1" colspan="1">41</td>
                          <td rowspan="1" colspan="1">15.8</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Very stable</td>
                          <td rowspan="1" colspan="1">40</td>
                          <td rowspan="1" colspan="1">29.6</td>
                          <td rowspan="1" colspan="1">30</td>
                          <td rowspan="1" colspan="1">24.0</td>
                          <td rowspan="1" colspan="1">70</td>
                          <td rowspan="1" colspan="1">26.9</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Don't know</td>
                          <td rowspan="1" colspan="1">2</td>
                          <td rowspan="1" colspan="1">1.5</td>
                          <td rowspan="1" colspan="1">4</td>
                          <td rowspan="1" colspan="1">3.2</td>
                          <td rowspan="1" colspan="1">6</td>
                          <td rowspan="1" colspan="1">2.3</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Choose not to answer</td>
                          <td rowspan="1" colspan="1">1</td>
                          <td rowspan="1" colspan="1">0.7</td>
                          <td rowspan="1" colspan="1">1</td>
                          <td rowspan="1" colspan="1">0.8</td>
                          <td rowspan="1" colspan="1">2</td>
                          <td rowspan="1" colspan="1">0.8</td>
                        </tr>
                        <tr>
                          <td colspan="2" rowspan="1">Monthly salary, mean (SD), CAD</td>
                          <td rowspan="1" colspan="1">760.30</td>
                          <td rowspan="1" colspan="1">1826.44</td>
                          <td rowspan="1" colspan="1">515.70</td>
                          <td rowspan="1" colspan="1">1032.48</td>
                          <td rowspan="1" colspan="1">642.70</td>
                          <td rowspan="1" colspan="1">1500.42</td>
                        </tr>
                        <tr>
                          <td colspan="2" rowspan="1">Marital status, <italic toggle="yes">n</italic> (%)</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Never married</td>
                          <td rowspan="1" colspan="1">80</td>
                          <td rowspan="1" colspan="1">59.3</td>
                          <td rowspan="1" colspan="1">91</td>
                          <td rowspan="1" colspan="1">72.8</td>
                          <td rowspan="1" colspan="1">171</td>
                          <td rowspan="1" colspan="1">65.8</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Married</td>
                          <td rowspan="1" colspan="1">3</td>
                          <td rowspan="1" colspan="1">2.2</td>
                          <td rowspan="1" colspan="1">5</td>
                          <td rowspan="1" colspan="1">4.0</td>
                          <td rowspan="1" colspan="1">8</td>
                          <td rowspan="1" colspan="1">3.1</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">In a relationship</td>
                          <td rowspan="1" colspan="1">18</td>
                          <td rowspan="1" colspan="1">13.3</td>
                          <td rowspan="1" colspan="1">8</td>
                          <td rowspan="1" colspan="1">6.4</td>
                          <td rowspan="1" colspan="1">26</td>
                          <td rowspan="1" colspan="1">10.0</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Divorced or separated</td>
                          <td rowspan="1" colspan="1">31</td>
                          <td rowspan="1" colspan="1">23.0</td>
                          <td rowspan="1" colspan="1">17</td>
                          <td rowspan="1" colspan="1">13.6</td>
                          <td rowspan="1" colspan="1">48</td>
                          <td rowspan="1" colspan="1">18.5</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Widowed</td>
                          <td rowspan="1" colspan="1">3</td>
                          <td rowspan="1" colspan="1">2.2</td>
                          <td rowspan="1" colspan="1">3</td>
                          <td rowspan="1" colspan="1">2.4</td>
                          <td rowspan="1" colspan="1">6</td>
                          <td rowspan="1" colspan="1">2.3</td>
                        </tr>
                        <tr>
                          <td colspan="2" rowspan="1">Risky behaviours in the last 30 days</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Injections with shared paraphernalia, <italic toggle="yes">n</italic> (%)</td>
                          <td rowspan="1" colspan="1">65</td>
                          <td rowspan="1" colspan="1">48.1</td>
                          <td rowspan="1" colspan="1">55</td>
                          <td rowspan="1" colspan="1">44.0</td>
                          <td rowspan="1" colspan="1">120</td>
                          <td rowspan="1" colspan="1">46.2</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Number of injections with shared paraphernalia, mean (SD)</td>
                          <td rowspan="1" colspan="1">1.42</td>
                          <td rowspan="1" colspan="1">6.16</td>
                          <td rowspan="1" colspan="1">4.6</td>
                          <td rowspan="1" colspan="1">21.96</td>
                          <td rowspan="1" colspan="1">2.90</td>
                          <td rowspan="1" colspan="1">15.55</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Unprotected sex, <italic toggle="yes">n</italic> (%)</td>
                          <td rowspan="1" colspan="1">70</td>
                          <td rowspan="1" colspan="1">51.9</td>
                          <td rowspan="1" colspan="1">62</td>
                          <td rowspan="1" colspan="1">49.6</td>
                          <td rowspan="1" colspan="1">132</td>
                          <td rowspan="1" colspan="1">50.8</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Number of sexual partners, mean (SD)</td>
                          <td rowspan="1" colspan="1">1.09</td>
                          <td rowspan="1" colspan="1">1.76</td>
                          <td rowspan="1" colspan="1">2.90</td>
                          <td rowspan="1" colspan="1">18.08</td>
                          <td rowspan="1" colspan="1">1.97</td>
                          <td rowspan="1" colspan="1">12.65</td>
                        </tr>
                        <tr>
                          <td colspan="2" rowspan="1">Medical comorbidities, <italic toggle="yes">n</italic> (%)</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Psychiatric</td>
                          <td rowspan="1" colspan="1">60</td>
                          <td rowspan="1" colspan="1">44.4</td>
                          <td rowspan="1" colspan="1">53</td>
                          <td rowspan="1" colspan="1">42.4</td>
                          <td rowspan="1" colspan="1">113</td>
                          <td rowspan="1" colspan="1">43.5</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Musculoskeletal</td>
                          <td rowspan="1" colspan="1">38</td>
                          <td rowspan="1" colspan="1">28.1</td>
                          <td rowspan="1" colspan="1">25</td>
                          <td rowspan="1" colspan="1">20.0</td>
                          <td rowspan="1" colspan="1">63</td>
                          <td rowspan="1" colspan="1">24.2</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Allergies</td>
                          <td rowspan="1" colspan="1">27</td>
                          <td rowspan="1" colspan="1">20.0</td>
                          <td rowspan="1" colspan="1">34</td>
                          <td rowspan="1" colspan="1">27.2</td>
                          <td rowspan="1" colspan="1">61</td>
                          <td rowspan="1" colspan="1">23.5</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Hepatobiliary</td>
                          <td rowspan="1" colspan="1">26</td>
                          <td rowspan="1" colspan="1">19.3</td>
                          <td rowspan="1" colspan="1">24</td>
                          <td rowspan="1" colspan="1">19.2</td>
                          <td rowspan="1" colspan="1">50</td>
                          <td rowspan="1" colspan="1">19.2</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Respiratory and throat</td>
                          <td rowspan="1" colspan="1">28</td>
                          <td rowspan="1" colspan="1">20.7</td>
                          <td rowspan="1" colspan="1">20</td>
                          <td rowspan="1" colspan="1">16.0</td>
                          <td rowspan="1" colspan="1">48</td>
                          <td rowspan="1" colspan="1">18.5</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Dermatological</td>
                          <td rowspan="1" colspan="1">14</td>
                          <td rowspan="1" colspan="1">10.4</td>
                          <td rowspan="1" colspan="1">18</td>
                          <td rowspan="1" colspan="1">14.4</td>
                          <td rowspan="1" colspan="1">32</td>
                          <td rowspan="1" colspan="1">12.3</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Gastrointestinal</td>
                          <td rowspan="1" colspan="1">11</td>
                          <td rowspan="1" colspan="1">8.2</td>
                          <td rowspan="1" colspan="1">20</td>
                          <td rowspan="1" colspan="1">16.0</td>
                          <td rowspan="1" colspan="1">31</td>
                          <td rowspan="1" colspan="1">11.9</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">HCV positive</td>
                          <td rowspan="1" colspan="1">14</td>
                          <td rowspan="1" colspan="1">11.1</td>
                          <td rowspan="1" colspan="1">18</td>
                          <td rowspan="1" colspan="1">15.1</td>
                          <td rowspan="1" colspan="1">32</td>
                          <td rowspan="1" colspan="1">13.1</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Cardiovascular</td>
                          <td rowspan="1" colspan="1">12</td>
                          <td rowspan="1" colspan="1">8.9</td>
                          <td rowspan="1" colspan="1">7</td>
                          <td rowspan="1" colspan="1">5.6</td>
                          <td rowspan="1" colspan="1">19</td>
                          <td rowspan="1" colspan="1">7.3</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Endocrine</td>
                          <td rowspan="1" colspan="1">6</td>
                          <td rowspan="1" colspan="1">4.4</td>
                          <td rowspan="1" colspan="1">8</td>
                          <td rowspan="1" colspan="1">6.4</td>
                          <td rowspan="1" colspan="1">14</td>
                          <td rowspan="1" colspan="1">5.4</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Eye, ear, nose and throat</td>
                          <td rowspan="1" colspan="1">6</td>
                          <td rowspan="1" colspan="1">4.4</td>
                          <td rowspan="1" colspan="1">9</td>
                          <td rowspan="1" colspan="1">7.2</td>
                          <td rowspan="1" colspan="1">15</td>
                          <td rowspan="1" colspan="1">5.8</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Genitourinary</td>
                          <td rowspan="1" colspan="1">10</td>
                          <td rowspan="1" colspan="1">7.4</td>
                          <td rowspan="1" colspan="1">4</td>
                          <td rowspan="1" colspan="1">3.2</td>
                          <td rowspan="1" colspan="1">14</td>
                          <td rowspan="1" colspan="1">5.4</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Neurological (stroke)</td>
                          <td rowspan="1" colspan="1">7</td>
                          <td rowspan="1" colspan="1">5.2</td>
                          <td rowspan="1" colspan="1">3</td>
                          <td rowspan="1" colspan="1">2.4</td>
                          <td rowspan="1" colspan="1">10</td>
                          <td rowspan="1" colspan="1">3.9</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Hematological</td>
                          <td rowspan="1" colspan="1">5</td>
                          <td rowspan="1" colspan="1">3.7</td>
                          <td rowspan="1" colspan="1">3</td>
                          <td rowspan="1" colspan="1">2.4</td>
                          <td rowspan="1" colspan="1">8</td>
                          <td rowspan="1" colspan="1">3.1</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">HIV positive</td>
                          <td rowspan="1" colspan="1">2</td>
                          <td rowspan="1" colspan="1">1.5</td>
                          <td rowspan="1" colspan="1">4</td>
                          <td rowspan="1" colspan="1">3.2</td>
                          <td rowspan="1" colspan="1">6</td>
                          <td rowspan="1" colspan="1">2.3</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Immunological</td>
                          <td rowspan="1" colspan="1">2</td>
                          <td rowspan="1" colspan="1">1.5</td>
                          <td rowspan="1" colspan="1">1</td>
                          <td rowspan="1" colspan="1">0.8</td>
                          <td rowspan="1" colspan="1">3</td>
                          <td rowspan="1" colspan="1">1.2</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Neoplasia (tumor)</td>
                          <td rowspan="1" colspan="1">1</td>
                          <td rowspan="1" colspan="1">0.7</td>
                          <td rowspan="1" colspan="1">2</td>
                          <td rowspan="1" colspan="1">1.6</td>
                          <td rowspan="1" colspan="1">3</td>
                          <td rowspan="1" colspan="1">1.2</td>
                        </tr>
                        <tr>
                          <td colspan="2" rowspan="1">Depressive symptoms score, mean (SD)</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Overall</td>
                          <td rowspan="1" colspan="1">22.7</td>
                          <td rowspan="1" colspan="1">14.3</td>
                          <td rowspan="1" colspan="1">20.9</td>
                          <td rowspan="1" colspan="1">13.4</td>
                          <td rowspan="1" colspan="1">21.6</td>
                          <td rowspan="1" colspan="1">13.9</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Baseline</td>
                          <td rowspan="1" colspan="1">26.8</td>
                          <td rowspan="1" colspan="1">12.4</td>
                          <td rowspan="1" colspan="1">23.7</td>
                          <td rowspan="1" colspan="1">12.3</td>
                          <td rowspan="1" colspan="1">25.3</td>
                          <td rowspan="1" colspan="1">12.5</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Week 12</td>
                          <td rowspan="1" colspan="1">20.1</td>
                          <td rowspan="1" colspan="1">13.9</td>
                          <td rowspan="1" colspan="1">21.1</td>
                          <td rowspan="1" colspan="1">13.4</td>
                          <td rowspan="1" colspan="1">20.6</td>
                          <td rowspan="1" colspan="1">13.6</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Week 24</td>
                          <td rowspan="1" colspan="1">15.2</td>
                          <td rowspan="1" colspan="1">15.0</td>
                          <td rowspan="1" colspan="1">15.9</td>
                          <td rowspan="1" colspan="1">14.2</td>
                          <td rowspan="1" colspan="1">15.5</td>
                          <td rowspan="1" colspan="1">14.5</td>
                        </tr>
                        <tr>
                          <td colspan="2" rowspan="1">Days of opioid use in the past two weeks, mean (SD)</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Overall</td>
                          <td rowspan="1" colspan="1">9.8</td>
                          <td rowspan="1" colspan="1">5.8</td>
                          <td rowspan="1" colspan="1">10.3</td>
                          <td rowspan="1" colspan="1">5.5</td>
                          <td rowspan="1" colspan="1">10.1</td>
                          <td rowspan="1" colspan="1">5.6</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Baseline</td>
                          <td rowspan="1" colspan="1">12.1</td>
                          <td rowspan="1" colspan="1">3.9</td>
                          <td rowspan="1" colspan="1">12.3</td>
                          <td rowspan="1" colspan="1">3.7</td>
                          <td rowspan="1" colspan="1">12.2</td>
                          <td rowspan="1" colspan="1">38</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Week 12</td>
                          <td rowspan="1" colspan="1">6.7</td>
                          <td rowspan="1" colspan="1">6.5</td>
                          <td rowspan="1" colspan="1">7.8</td>
                          <td rowspan="1" colspan="1">6.3</td>
                          <td rowspan="1" colspan="1">7.2</td>
                          <td rowspan="1" colspan="1">6.4</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">Week 24</td>
                          <td rowspan="1" colspan="1">10.8</td>
                          <td rowspan="1" colspan="1">5.0</td>
                          <td rowspan="1" colspan="1">11.0</td>
                          <td rowspan="1" colspan="1">5.1</td>
                          <td rowspan="1" colspan="1">10.9</td>
                          <td rowspan="1" colspan="1">5.1</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="table-fn1-07067437221145013">
                      <p>BUP/NX: Buprenorphine/Naloxone; CAD: Canadian dollars; <italic toggle="yes">n</italic>: number of participants; SD: standard deviation.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="section4B-07067437221145013">
                <title>Depressive Symptoms Scores</title>
                <p>Mean depressive symptoms scores in both methadone and BUP/NX groups throughout study visits are reported in <xref rid="table1-07067437221145013" ref-type="table">Table 1</xref> and illustrated in <xref rid="fig2-07067437221145013" ref-type="fig">Figure 2</xref>. Baseline average depressive symptoms scores (±SD) were similar between treatments, with 23.66 (±12.26) for methadone and 26.84 (±12.44) for BUP/NX, indicating moderate depression severity. For methadone, mean depressive symptoms (±SD) showed a constant decrease, reaching 21.11 (±13.35) at week 12 and 15.87 (±14.17) at week 24. The same pattern was observed with BUP/NX with a mean depressive symptom (±SD) of 20.08 (±13.92) at week 12 and 15.17 (±14.99) at week 24.</p>
                <fig position="float" id="fig2-07067437221145013">
                  <label>Figure 2.</label>
                  <caption>
                    <p>Mean (±SD) depressive symptoms scores across study visits for methadone and buprenorphine/naloxone treatment groups. Baseline depressive scores were similar between treatment groups. Depressive symptoms showed a constant decrease throughout the study period. BDI-II, Beck Depression Inventory – Second Edition.</p>
                  </caption>
                  <graphic xlink:href="10.1177_07067437221145013-fig2" position="float"/>
                </fig>
              </sec>
              <sec id="section4C-07067437221145013">
                <title>Main Results</title>
                <p><xref rid="table2-07067437221145013" ref-type="table">Table 2</xref> reports the results of the adjusted rmGLM models. Participants receiving methadone had less severe overall depressive symptoms compared to BUP/NX (aβ ± standard error [SE] = 3.298 ± 1.604; <italic toggle="yes">P</italic> = 0.041). We also found a statistically significant effect of study visits (aβ ± SE = −3.167 ± 1.233 for week 12; aβ ± SE = −7.280 ± 1.285 for week 24; <italic toggle="yes">P</italic> &lt; 0.001), indicating a significant decrease in depressive symptoms throughout the study. When adjusting for lifetime heroin use and study site, there was a significant difference in depressive symptoms between baseline and week 12 (aβ ± SE = −4.470 ± 0.889; <italic toggle="yes">P</italic> &lt; 0.001), baseline and week 24 (aβ ± SE = −8.340 ± 0.928; <italic toggle="yes">P</italic> &lt; 0.001), and week 12 and week 24 (aβ ± SE = −3.870 ± 0.978; <italic toggle="yes">P</italic> &lt; 0.001). The interaction between treatment and visits was not significant (aβ ± SE = −2.696 ± 1.775 for week 12 and BUP/NX; aβ ± SE = −1.960 ± 1.849 for week 24 and BUP/NX; <italic toggle="yes">P</italic> = 0.284), indicating that decreases in depressive symptoms occurred at a similar rate in both groups. We found an impact of the study site (<italic toggle="yes">P</italic> = 0.031), with significantly lower depressive symptoms reported by participants from the Centre hospitalier de l’Université de Montréal (Montréal, QC) compared to participants from the Opioid Dependency Program Clinic (Calgary and Edmonton, AB) (aβ ± SE = −6.781 ± 2.030; <italic toggle="yes">P</italic> = 0.017). Lifetime heroin use (<italic toggle="yes">P</italic> = 0.394) did not impact estimates.</p>
                <table-wrap position="float" id="table2-07067437221145013">
                  <label>Table 2.</label>
                  <caption>
                    <p>Results from the Repeated Measured Generalised Linear Model for Depressive Symptoms.</p>
                  </caption>
                  <alternatives>
                    <graphic xlink:href="10.1177_07067437221145013-table2" position="float"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" rowspan="1" colspan="1">Variables</th>
                          <th align="left" rowspan="1" colspan="1">Coefficients</th>
                          <th align="left" rowspan="1" colspan="1">Standard Error</th>
                          <th align="left" rowspan="1" colspan="1"><italic toggle="yes">t</italic>-value</th>
                          <th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td rowspan="1" colspan="1">Intercept</td>
                          <td rowspan="1" colspan="1">21.691</td>
                          <td rowspan="1" colspan="1">1.989</td>
                          <td rowspan="1" colspan="1">10.660</td>
                          <td rowspan="1" colspan="1">
                            <bold>&lt;0.001</bold>
                          </td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Visit</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">
                            <bold>&lt;0.001</bold>
                          </td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Week 12</td>
                          <td rowspan="1" colspan="1">−3.167</td>
                          <td rowspan="1" colspan="1">1.233</td>
                          <td rowspan="1" colspan="1">8.397</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Week 24</td>
                          <td rowspan="1" colspan="1">−7.280</td>
                          <td rowspan="1" colspan="1">1.285</td>
                          <td rowspan="1" colspan="1">−0.411</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Opioid agonist treatment</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1">
                            <bold>0.041</bold>
                          </td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> BUP/NX</td>
                          <td rowspan="1" colspan="1">3.298</td>
                          <td rowspan="1" colspan="1">1.604</td>
                          <td rowspan="1" colspan="1">−1.158</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Site</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1">
                            <bold>0.031</bold>
                          </td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> CHUM</td>
                          <td rowspan="1" colspan="1">−2.320</td>
                          <td rowspan="1" colspan="1">4.583</td>
                          <td rowspan="1" colspan="1">−1.021</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> CRAN</td>
                          <td rowspan="1" colspan="1">−3.228</td>
                          <td rowspan="1" colspan="1">4.583</td>
                          <td rowspan="1" colspan="1">−0.704</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> OATC</td>
                          <td rowspan="1" colspan="1">4.285</td>
                          <td rowspan="1" colspan="1">7.257</td>
                          <td rowspan="1" colspan="1">0.590</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> ODPC</td>
                          <td rowspan="1" colspan="1">4.417</td>
                          <td rowspan="1" colspan="1">2.332</td>
                          <td rowspan="1" colspan="1">1.894</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> PHSC</td>
                          <td rowspan="1" colspan="1">6.189</td>
                          <td rowspan="1" colspan="1">4.413</td>
                          <td rowspan="1" colspan="1">1.402</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> RAAC</td>
                          <td rowspan="1" colspan="1">0.296</td>
                          <td rowspan="1" colspan="1">2.498</td>
                          <td rowspan="1" colspan="1">0.119</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Lifetime heroin use</td>
                          <td rowspan="1" colspan="1">1.483</td>
                          <td rowspan="1" colspan="1">1.737</td>
                          <td rowspan="1" colspan="1">0.854</td>
                          <td rowspan="1" colspan="1">0.394</td>
                        </tr>
                        <tr>
                          <td colspan="5" rowspan="1">Visit*Opioid agonist treatment</td>
                          <td align="left" rowspan="1" colspan="1">0.284</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Week 12*BUP/NX</td>
                          <td rowspan="1" colspan="1">−2.696</td>
                          <td rowspan="1" colspan="1">1.775</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">−1.519</td>
                          <td rowspan="1" colspan="1">
</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Week 24*BUP/NX</td>
                          <td rowspan="1" colspan="1">−1.960</td>
                          <td rowspan="1" colspan="1">1.849</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">−1.060</td>
                          <td rowspan="1" colspan="1">
</td>
                        </tr>
                        <tr>
                          <td colspan="6" rowspan="1">Contrast: Visit</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Baseline vs Week 12</td>
                          <td rowspan="1" colspan="1">4.470</td>
                          <td rowspan="1" colspan="1">0.889</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">5.029</td>
                          <td rowspan="1" colspan="1">
                            <bold>&lt;0.001</bold>
                          </td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Baseline vs Week 24</td>
                          <td rowspan="1" colspan="1">8.340</td>
                          <td rowspan="1" colspan="1">0.928</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">8.994</td>
                          <td rowspan="1" colspan="1">
                            <bold>&lt;0.001</bold>
                          </td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Week 12 vs Week 24</td>
                          <td rowspan="1" colspan="1">3.870</td>
                          <td rowspan="1" colspan="1">0.978</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">3.957</td>
                          <td rowspan="1" colspan="1">
                            <bold>&lt;0.001</bold>
                          </td>
                        </tr>
                        <tr>
                          <td colspan="6" rowspan="1">Contrast: Site</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> CAMH vs CHUM</td>
                          <td rowspan="1" colspan="1">2.298</td>
                          <td rowspan="1" colspan="1">2.280</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">1.008</td>
                          <td rowspan="1" colspan="1">0.952</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> CAMH vs CRAN</td>
                          <td rowspan="1" colspan="1">3.185</td>
                          <td rowspan="1" colspan="1">4.600</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">0.692</td>
                          <td rowspan="1" colspan="1">0.993</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> CAMH vs OATC</td>
                          <td rowspan="1" colspan="1">−4.161</td>
                          <td rowspan="1" colspan="1">7.280</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">−0.572</td>
                          <td rowspan="1" colspan="1">0.998</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> CAMH vs ODPC</td>
                          <td rowspan="1" colspan="1">−4.482</td>
                          <td rowspan="1" colspan="1">2.340</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">−1.916</td>
                          <td rowspan="1" colspan="1">0.472</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> CAMH vs PHSC</td>
                          <td rowspan="1" colspan="1">−6.107</td>
                          <td rowspan="1" colspan="1">4.430</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">−1.379</td>
                          <td rowspan="1" colspan="1">0.813</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> CAMH vs RAAC</td>
                          <td rowspan="1" colspan="1">−0.321</td>
                          <td rowspan="1" colspan="1">2.510</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">−0.128</td>
                          <td rowspan="1" colspan="1">1.000</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> CHUM vs CRAN</td>
                          <td rowspan="1" colspan="1">0.887</td>
                          <td rowspan="1" colspan="1">4.560</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">0.195</td>
                          <td rowspan="1" colspan="1">1.000</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> CHUM vs OATC</td>
                          <td rowspan="1" colspan="1">−6.460</td>
                          <td rowspan="1" colspan="1">7.300</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">−0.885</td>
                          <td rowspan="1" colspan="1">0.975</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> CHUM vs ODPC</td>
                          <td rowspan="1" colspan="1">−6.781</td>
                          <td rowspan="1" colspan="1">2.030</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">−3.338</td>
                          <td rowspan="1" colspan="1">
                            <bold>0.017</bold>
                          </td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> CHUM vs PHSC</td>
                          <td rowspan="1" colspan="1">−8.405</td>
                          <td rowspan="1" colspan="1">4.250</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">−1.979</td>
                          <td rowspan="1" colspan="1">0.431</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> CHUM vs RAAC</td>
                          <td rowspan="1" colspan="1">−2.619</td>
                          <td rowspan="1" colspan="1">2.170</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">−1.204</td>
                          <td rowspan="1" colspan="1">0.892</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> CRAN vs OATC</td>
                          <td rowspan="1" colspan="1">−7.347</td>
                          <td rowspan="1" colspan="1">8.270</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">−0.888</td>
                          <td rowspan="1" colspan="1">0.974</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> CRAN vs ODPC</td>
                          <td rowspan="1" colspan="1">−7.668</td>
                          <td rowspan="1" colspan="1">4.600</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">−1.668</td>
                          <td rowspan="1" colspan="1">0.638</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> CRAN vs PHSC</td>
                          <td rowspan="1" colspan="1">−9.292</td>
                          <td rowspan="1" colspan="1">5.940</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">−1.564</td>
                          <td rowspan="1" colspan="1">0.705</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> CRAN vs RAAC</td>
                          <td rowspan="1" colspan="1">−3.506</td>
                          <td rowspan="1" colspan="1">4.680</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">−0.749</td>
                          <td rowspan="1" colspan="1">0.989</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> OATC vs ODPC</td>
                          <td rowspan="1" colspan="1">−0.321</td>
                          <td rowspan="1" colspan="1">7.330</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">−0.044</td>
                          <td rowspan="1" colspan="1">1.000</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> OATC vs PHSC</td>
                          <td rowspan="1" colspan="1">−1.946</td>
                          <td rowspan="1" colspan="1">8.260</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">−0.236</td>
                          <td rowspan="1" colspan="1">1.000</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> OATC vs RAAC</td>
                          <td rowspan="1" colspan="1">3.841</td>
                          <td rowspan="1" colspan="1">7.400</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">0.519</td>
                          <td rowspan="1" colspan="1">0.999</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> ODPC vs PHSC</td>
                          <td rowspan="1" colspan="1">−1.625</td>
                          <td rowspan="1" colspan="1">4.230</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">−0.384</td>
                          <td rowspan="1" colspan="1">1.000</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> ODPC vs RAAC</td>
                          <td rowspan="1" colspan="1">4.162</td>
                          <td rowspan="1" colspan="1">2.150</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">1.938</td>
                          <td rowspan="1" colspan="1">0.457</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> PHSC vs RAAC</td>
                          <td rowspan="1" colspan="1">5.786</td>
                          <td rowspan="1" colspan="1">4.300</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td rowspan="1" colspan="1">1.346</td>
                          <td rowspan="1" colspan="1">0.829</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">AIC</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td align="left" colspan="3" rowspan="1">4157.044</td>
                          <td rowspan="1" colspan="1">
</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">BIC</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td align="left" colspan="3" rowspan="1">4221.556</td>
                          <td rowspan="1" colspan="1">
</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Log-likelihood</td>
                          <td rowspan="1" colspan="1">
</td>
                          <td align="left" colspan="3" rowspan="1">−2063.522</td>
                          <td rowspan="1" colspan="1">
</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="table-fn2-07067437221145013">
                      <p>The Centre for Addiction and Mental Health (CAMH) was used as the reference site.</p>
                    </fn>
                    <fn id="table-fn3-07067437221145013">
                      <p>AIC: Akaike Information Criterion; BIC: Bayesian Information Criterion; BUP/NX: buprenorphine/naloxone; CAMH: Centre for Addiction and Mental Health; CHUM: Centre hospitalier de l'Université de Montréal; CRAN: Centre de Recherche et d'Aide pour Narcomanes; OATC: Ontario Addiction Treatment Centre; ODPC: Opioid Dependency Program Clinic; PHSC: Portland Hotel Society Medical Clinic; RAAC: Rapid Access Addiction Clinic.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="section4D-07067437221145013">
                <title>Mediation Analyses</title>
                <p><ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/07067437221145013" ext-link-type="uri">Table S1</ext-link> reports the models estimated for the mediation analyses. <ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/07067437221145013" ext-link-type="uri">Table S2</ext-link> and <xref rid="fig3-07067437221145013" ref-type="fig">Figure 3</xref> illustrate the mediation analyses using imputed data. Being on OAT at week 12 or week 24 significantly reduced days of opioid use (<italic toggle="yes">P</italic> &lt; 0.001) and depressive symptoms (<italic toggle="yes">P</italic> &lt; 0.001). Reductions in opioid use further decreased depressive symptoms between baseline and week 12 (<italic toggle="yes">P</italic> = 0.003), between week 12 and week 24 (all <italic toggle="yes">P</italic> &lt; 0.01), and between baseline and week 24 (<italic toggle="yes">P</italic> &lt; 0.001).</p>
                <fig position="float" id="fig3-07067437221145013">
                  <label>Figure 3.</label>
                  <caption>
                    <p>Results from the mediation analyses using imputed data. (A) Being on opioid agonist treatment from baseline to week 12 significantly reduced days of opioid use (<italic toggle="yes">P</italic> &lt; 0.001) and depressive symptoms (<italic toggle="yes">P</italic> &lt; 0.001) at week 12. Days of opioid use in the past two weeks predicted depressive symptoms at week 12 (<italic toggle="yes">P</italic> = 0.003). The direct path (<italic toggle="yes">P</italic> = 0.001) and total effect (<italic toggle="yes">P</italic> &lt; 0.001) were significant. The mediated effect was not significant (<italic toggle="yes">P</italic> = 0.281). (B) Being on opioid agonist treatment from baseline to week 24 significantly reduced days of opioid use (<italic toggle="yes">P</italic> &lt; 0.001) and depressive symptoms (<italic toggle="yes">P</italic> &lt; 0.001) at week 24. The combined effect of time on OAT and days of opioid use in the past two weeks significantly decreased depressive symptoms at week 24 (<italic toggle="yes">P</italic> &lt; 0.001). The direct effect (<italic toggle="yes">P</italic> &lt; 0.001), and the total effect (<italic toggle="yes">P</italic> &lt; 0.001) were significant, while the mediated effect was not (<italic toggle="yes">P</italic> = 0.140). (C) Being on opioid agonist treatment from week 12 to week 24 significantly decreased depressive symptoms at week 24 (<italic toggle="yes">P</italic> = 0.002) but increased days of opioid use at week 24 (<italic toggle="yes">P</italic> = 0.002). The indirect (<italic toggle="yes">P</italic> = 0.014), direct (<italic toggle="yes">P</italic> &lt; 0.001) and total (<italic toggle="yes">P</italic> = 0.001) effects were all significant.</p>
                  </caption>
                  <graphic xlink:href="10.1177_07067437221145013-fig3" position="float"/>
                </fig>
                <p>From baseline to week 12, the direct (<italic toggle="yes">P</italic> = 0.001) and total (<italic toggle="yes">P</italic> &lt; 0.001) effects were significant. The mediated effect was not significant (<italic toggle="yes">P</italic> = 0.281). From baseline to week 24, the direct and combined paths were significant (<italic toggle="yes">P</italic> &lt; 0.001), while the mediated path was not (<italic toggle="yes">P</italic> = 0.140). From week 12 to week 24, the direct (<italic toggle="yes">P</italic> &lt; 0.001), mediated (<italic toggle="yes">P</italic> = 0.014), and total effects (<italic toggle="yes">P</italic> &lt; 0.001) were significant. Opioid use accounted for 17.1% of the variance (<italic toggle="yes">P</italic> = 0.281) from baseline to week 12, 3.9% (<italic toggle="yes">P</italic> = 0.140) from baseline to week 24, and 36.5% (<italic toggle="yes">P</italic> = 0.015) from week 12 to week 24.</p>
              </sec>
              <sec id="section4E-07067437221145013">
                <title>Subgroup Mediation Analyses</title>
                <p><ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/07067437221145013" ext-link-type="uri">Figure S1</ext-link> and <ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/07067437221145013" ext-link-type="uri">Table S2</ext-link> report the subgroup mediation analyses. For methadone, the direct and total effects were significant from baseline to week 12 (<italic toggle="yes">P</italic> &lt; 0.01) and from baseline to week 24 (<italic toggle="yes">P</italic> &lt; 0.001). Moreover, the direct (<italic toggle="yes">P</italic> = 0.013) and total (<italic toggle="yes">P</italic> = 0.002) effects were significant from week 12 to week 24. The mediated effect was borderline significant between week 12 and week 24 (<italic toggle="yes">P</italic> = 0.052), with opioid use accounting for 30.9% of the variance (<italic toggle="yes">P</italic> = 0.065). For BUP/NX, the total effect was significant from baseline to week 12 (<italic toggle="yes">P</italic> = 0.002). The mediated effect was not significant (<italic toggle="yes">P</italic> = 0.131) and accounted for 38.3% of the variance (<italic toggle="yes">P</italic> = 0.132). The direct effect was borderline significant (<italic toggle="yes">P</italic> = 0.079). From baseline to week 24, the total and direct effects were significant (<italic toggle="yes">P</italic> &lt; 0.001). The mediated effect was borderline significant (<italic toggle="yes">P</italic> = 0.056) and accounted for 7.4% (<italic toggle="yes">P</italic> = 0.056) of the variance. From week 12 to week 24, the total (<italic toggle="yes">P</italic> = 0.017) and direct (<italic toggle="yes">P</italic> = 0.002) effects were significant. The mediated effect was not (<italic toggle="yes">P</italic> = 0.133) and accounted for 36.7% of the variance (<italic toggle="yes">P</italic> = 0.150).</p>
              </sec>
              <sec id="section4F-07067437221145013">
                <title>Sensitivity Analyses</title>
                <p>Per-protocol and COVID-19 sensitivity analyses confirmed our results (see <ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/07067437221145013" ext-link-type="uri">Table S3</ext-link>). However, as opposed to our main analysis, BUP/NX did not report overall higher depressive symptoms (marginal mean ± SE for methadone = 21.1 ± 2.1; marginal mean ± SE for BUP/NX = 18.0 ± SE 2.2; mean difference ± SE = 2.047 ± 2.995; <italic toggle="yes">P</italic> = 0.496) compared to methadone in retained participants (see <ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/07067437221145013" ext-link-type="uri">Table S3</ext-link>). To explain these results, we tested for characteristics differences between retained and not retained participants (see <ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/07067437221145013" ext-link-type="uri">Table S4</ext-link>). Retained participants were more likely to be white (<italic toggle="yes">P</italic> = 0.009), male (<italic toggle="yes">P</italic> = 0.024), and men (<italic toggle="yes">P</italic> = 0.042), have never used heroin in their lifetime (<italic toggle="yes">P</italic> = 0.027), have provincial drug coverage (<italic toggle="yes">P</italic> &lt; 0.001), greater housing stability (<italic toggle="yes">P</italic> = 0.008), and higher monthly income (<italic toggle="yes">P</italic> = 0.007). They were also more likely to report reduced overall depressive symptoms (<italic toggle="yes">P</italic> &lt; 0.001) and opioid use (<italic toggle="yes">P</italic> &lt; 0.001) compared to non-retained participants.</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="section5-07067437221145013">
              <title>Discussion</title>
              <p>To our knowledge, this is the first study to compare the impact of methadone and BUP/NX in decreasing depressive symptoms in people with POUD. Both treatments improved depressive symptoms at a similar rate. This effect was partially mediated by days of opioid use, especially for methadone and during the last 12 weeks of treatment.</p>
              <p>Many factors could explain these results. For one, chronic opioid use is known to induce depressive symptoms.<sup><xref rid="bibr32-07067437221145013" ref-type="bibr">32</xref>,<xref rid="bibr34-07067437221145013" ref-type="bibr">34</xref></sup> Therefore, by reducing opioid use in the first 12 weeks of treatment, OATs decreased opioid-induced depressive symptoms in the subsequent weeks. The quantity of opioids used during each day might also be lower. However, reductions in opioid use only account for a small proportion of improvements, therefore, suggesting the involvement of other pathways leading to an overall antidepressant effect.</p>
              <p>First, BUP/NX can help with depressive symptomatology in people with treatment-resistant depression, possibly through the opioid, endocrinological, and serotoninergic systems.<sup><xref rid="bibr10-07067437221145013" ref-type="bibr">10</xref>,<xref rid="bibr19-07067437221145013" ref-type="bibr">19</xref>,<xref rid="bibr24-07067437221145013" ref-type="bibr">24</xref></sup> Although long-term methadone treatment can lead to induced dysphoria through hormonal dysregulations,<sup><xref rid="bibr35-07067437221145013" ref-type="bibr">35</xref>,<xref rid="bibr36-07067437221145013" ref-type="bibr">36</xref></sup> it has similarly been reported to decrease depressive symptoms, alone or in conjunction with antidepressants.<sup><xref rid="bibr20-07067437221145013" ref-type="bibr">20</xref>,<xref rid="bibr22-07067437221145013" ref-type="bibr">22</xref>,<xref rid="bibr24-07067437221145013" ref-type="bibr">24</xref></sup> Many studies have reported that both BUP/NX and methadone can help with depressive symptoms independently of opioid use.<sup><xref rid="bibr10-07067437221145013" ref-type="bibr">10</xref>,<xref rid="bibr17-07067437221145013" ref-type="bibr">17</xref>,<xref rid="bibr20-07067437221145013" ref-type="bibr">20</xref></sup> Therefore, the current evidence underlies that OATs potentially have intrinsic antidepressant properties.</p>
              <p>However, beyond the reduction of opioid use and OAT's pharmacological actions, many other OAT-related factors might have lowered depressive symptoms. For example, a previous report of the current study showed that both methadone and BUP/NX increased overall quality of life,<sup><xref rid="bibr29-07067437221145013" ref-type="bibr">29</xref></sup> which may indicate reduced hopelessness, better hygiene/self-care, and increased involvement in activities. Another report showed that both treatment arms decreased craving frequency, length, and intensity at a similar rate.<sup><xref rid="bibr37-07067437221145013" ref-type="bibr">37</xref></sup> Both methadone and BUP/NX can also lower withdrawal symptoms, which are associated with increased anxiety and dysphoric moods.<sup><xref rid="bibr38-07067437221145013" ref-type="bibr">38</xref>,<xref rid="bibr39-07067437221145013" ref-type="bibr">39</xref></sup> Therefore, by reducing cravings and withdrawal symptoms, both OATs could have reduced anxiety and depressive states, leading to improvements in overall well-being. Also, access to mental health interventions might have been facilitated by the fact that participants were followed at OAT clinics. These interventions could have directly or indirectly reduced primary depressive symptoms. Due to the pragmatic design, access to certain types of mental health interventions (including antidepressants and psychotherapy) may have varied based on geographical location, which could explain differences across study sites. Finally, in the absence of a placebo arm, we cannot exclude a possible Hawthorne effect (i.e., changes in behaviours that could improve physical, psychological, social, and environmental functioning) leading to reduced depressive symptoms.<sup><xref rid="bibr40-07067437221145013" ref-type="bibr">40</xref></sup> However, many studies looking at methadone or BUP/NX found that these OATs lead to reductions in depressive symptoms comparable to antidepressants and psychotherapy.<sup><xref rid="bibr10-07067437221145013" ref-type="bibr">10</xref>,<xref rid="bibr20-07067437221145013" ref-type="bibr">20</xref>,<xref rid="bibr22-07067437221145013" ref-type="bibr">22</xref>,<xref rid="bibr24-07067437221145013" ref-type="bibr">24</xref>,<xref rid="bibr41-07067437221145013" ref-type="bibr">41</xref></sup> Therefore, even if a placebo effect is involved in the improvements seen in depressive symptoms, OATs seem to have an efficacy similar to traditional depression treatments.</p>
              <p>Although we found no interaction of treatment and time, depressive symptoms in BUP/NX were on average 3 points higher than methadone. Sensitivity analyses with retained participants did not lead to the same overall difference. This discrepancy seemed to be explained by differences in characteristics between retained and nonretained participants, and BUP/NX participants being less likely to be retained in treatment. Overall opioid use was higher in participants who were not considered as retained. Nonretained participants had also a higher prevalence of some risk factors, such as housing instability,<sup><xref rid="bibr42-07067437221145013" ref-type="bibr">42</xref></sup> female sex,<sup><xref rid="bibr43-07067437221145013" ref-type="bibr">43</xref></sup> lower income,<sup><xref rid="bibr42-07067437221145013" ref-type="bibr">42</xref>,<xref rid="bibr44-07067437221145013" ref-type="bibr">44</xref></sup> having no drug coverage,<sup><xref rid="bibr45-07067437221145013" ref-type="bibr">45</xref></sup> and physical/psychiatric comorbidities,<sup><xref rid="bibr46-07067437221145013" ref-type="bibr">46</xref>,<xref rid="bibr47-07067437221145013" ref-type="bibr">47</xref></sup> notably more severe depressive symptoms. Previous studies have shown that BUP/NX might lead to lower retention in people with more severe POUD.<sup><xref rid="bibr48-07067437221145013" ref-type="bibr">48</xref>,<xref rid="bibr50-07067437221145013" ref-type="bibr">50</xref></sup> As a partial agonist of opioid receptors, BUP/NX leads to a submaximal activation, even at maximum occupancy of µ-opioid receptors.<sup><xref rid="bibr51-07067437221145013" ref-type="bibr">51</xref></sup> Methadone allows an increased activation of the opioid receptors at higher doses.<sup><xref rid="bibr52-07067437221145013" ref-type="bibr">52</xref></sup> Consequently, its total agonist effect may make it more suitable for some people who use heavily,<sup><xref rid="bibr53-07067437221145013" ref-type="bibr">53</xref>,<xref rid="bibr54-07067437221145013" ref-type="bibr">54</xref></sup> or, such as it is the case in our sample, use highly potent opioids. We might expect that more people with severe POUD switched to another OAT or discontinued treatment and were, therefore, excluded from the retained analyses. Altogether, this may indicate that while participants retained on BUP/NX may report improved depressive symptoms, this OAT is more likely to lead to a treatment switch.<sup><xref rid="bibr29-07067437221145013" ref-type="bibr">29</xref></sup> Any specific positive effect of BUP/NX may need to be balanced with this lower likelihood of retention, even more so in people with other risk factors for treatment non-adherence.</p>
              <p>Since methadone and BUP/NX showed similar trends and pathways in decreasing depressive symptoms, clinicians are encouraged to tailor the selection of OAT to the full array of patients’ needs and characteristics.<sup><xref rid="bibr54-07067437221145013" ref-type="bibr">54</xref></sup> Assessing patient preferences regarding OAT is also highly relevant in the treatment of POUD and comorbid depression. A recent study on patient preferences for OATs identified that people with OUD attributed many advantages to BUP/NX over methadone, such as the easier switch from BUP/NX to methadone, increased flexibility with take-home doses, less sedation effects, and increased perceived efficacy.<sup><xref rid="bibr55-07067437221145013" ref-type="bibr">55</xref></sup> Tailoring treatment to patient preferences and needs, including but not only based on the presence of depressive symptoms, might lead to increased treatment adherence and better outcomes.<sup><xref rid="bibr56-07067437221145013" ref-type="bibr">56</xref></sup></p>
              <sec id="section5A-07067437221145013">
                <title>Limitations</title>
                <p>This study is not without limitations. Firstly, we had a 44% attrition rate that could have impacted our results. Indeed, most participants not considered as retained showed more psychosocial risk factors. Therefore, we might expect that participants that were more likely to have a beneficial impact on the interventions were retained in treatment. Future studies should explore if our results can be extrapolated to people with more severe psychosocial functioning. Secondly, without a placebo arm, it is impossible to make conclusions about the independent effectiveness of OATs in decreasing depressive symptoms. Our data have shown, however, that having access to methadone or BUP/NX can improve depressive symptoms through a variety of possible mechanisms. Thirdly, having a pragmatic nonblinded design might have biased our data and included more confounders. For example, access to and delivery of other interventions were not standardised across study sites. Fourthly, this randomised controlled trial was not primarily designed to investigate the impact of OATs on depressive symptoms. This secondary analysis is, however, still informative of the possible mechanisms involved in the association between OATs and depressive symptoms. Lastly, we only measured depressive symptoms at week 12 and week 24. Since we did not assess a diagnosis of depression, readers should keep in mind that this study focuses on nonspecified depressive symptoms. Also, we might have found different patterns during the first few weeks of OAT or after 24 weeks. Further trials should be conducted to evaluate whether OATs differ in the very short or long term.</p>
              </sec>
            </sec>
            <sec id="section6-07067437221145013">
              <title>Conclusion Statements</title>
              <p>Both the methadone standard model of care and flexible take-home dosing of BUP/NX similarly decreased depressive symptoms in people with POUD. Improvements in depressive symptoms were partially explained by a reduction in days of opioid use. As both treatments are equally effective, clinicians are encouraged to discuss both benefits and disadvantages of OATs and make a shared decision with the patient on which treatment to choose. Future research should investigate how patient preferences and characteristics, such as specific patterns of opioid use or other mental health markers, are likely to influence OAT outcomes.</p>
            </sec>
            <sec sec-type="supplementary-material" specific-use="figshare">
              <title>Supplemental Material</title>
              <supplementary-material id="supp1-07067437221145013" position="float" content-type="local-data">
                <caption>
                  <title>sj-docx-1-cpa-10.1177_07067437221145013 - Supplemental material for Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial</title>
                </caption>
                <media xlink:href="sj-docx-1-cpa-10.1177_07067437221145013.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
                <p>Supplemental material, sj-docx-1-cpa-10.1177_07067437221145013 for Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial by Gabriel Bastien, Christina McAnulty, Omar Ledjiar, M. Eugenia Socias, Bernard Le Foll, Ron Lim, Ahmed N. Hassan, Suzanne Brissette, Stéphanie Marsan, Annie Talbot, Didier Jutras-Aswad and in The Canadian Journal of Psychiatry</p>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <title>Acknowledgments</title>
              <p>The authors would like to acknowledge the work of Denise Adams, Oluwadamilola Akinyemi, Benoit Masse, Jill Fikowski, Aïssata Sako, Katrina Blommaert, Emma Garrod, José Trigo, Amel Zertal, Nirupa Goel, Farihah Ali, Wendy Mauro-Allard, Kristen Morin, Benita Okacha, Eve Poirier, Geneviève St-Onge, and Angela Wallace for assisting in the conduction and administration of the trial. Our team expresses gratitude to Kim Brochu for her clinical input. The authors also thank Léa Gagnon and Helen Kang for reviewing and editing the manuscript. Finally, our team would like to thank all participants and clinical staff who took part in this research.</p>
            </ack>
            <fn-group>
              <fn fn-type="other">
                <p><bold>Data Access:</bold> Following publication, individual deidentified participant data and a data dictionary can be made available upon reasonable request from JF at <ext-link xlink:href="jill.fikowski.chum@ssss.gouv.qc.ca" ext-link-type="uri">jill.fikowski.chum@ssss.gouv.qc.ca</ext-link>, following approval of a proposal and a signed data access agreement. Please also contact this person for the study protocol or statistical analysis plan.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Authors’ Note:</bold> GB received scholarships from the Institut universitaire sur les dépendances, the Quebec Network on Suicide, Mood Disorders and Related Disorders, and the Centre hospitalier de l’Université de Montréal Research Centre. CM received funding from the Institut universitaire sur les dépendances, the Gaulin Foundation and the Centre hospitalier de l’Université de Montréal Research Centre. MES is supported by a Michael Smith Foundation for Health Research and St. Paul's Foundation Scholar Award. BLF is supported by a clinician scientist award from the Department of Family and Community Medicine and by the Addiction Psychiatry Chair of the Department of Psychiatry, University of Toronto. BLF receives or has received support from Pfizer Global Research Awards in Nicotine Dependence (GRAND) Program, Brainsway, Bioprojet, Alkermes, Canopy, ACS, and non-financial support from Aurora for work outside this study. KA was supported by an Embedded Clinician Researcher Salary Award from the Canadian Institutes of Health Research. DJA holds a research scholar award from the Fonds de Recherche du Québec en Santé. OPTIMA Research Group: <bold>Alberta.</bold> Susan Bornemisza, Helen Bouman, Sarah Elliott, Laura Evans, Monty Ghosh, Lucas Gursky, Lydia Vezina, Cam Wild, Alvis Yu; <bold>British Columbia.</bold> Paxton Bach, Rupinder Brar, Nadia Fairbairn, Christopher Fairgrieve, Sonia Habibian, Sukhpreet Klaire, Scott MacDonald, Mark McLean, Seonaid Christine Nolan, Gerrit Prinsloo, Christy Sutherland, Evan Wood; <bold>Ontario.</bold> Nikki Bozinoff, Benedikt Fischer, Mike Franklin, Ahmed Hassan, Dafna Kahana, Dina Lagzdins, David Marsh, Jürgen Rehm; <bold>Quebec.</bold> David Barbeau, Julie Bruneau, Louis-Christophe Juteau, Sidney Maynard. This study was registered in ClinicalTrials.gov (NCT03033732). Research Centre, CHUM (CRCHUM), Montréal, Québec, Canada.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
              </fn>
              <fn fn-type="financial-disclosure">
                <p><bold>Funding:</bold> The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by funds received from Health Canada and the Canadian Institutes of Health Research (CIHR) through the Canadian Research Initiative in Substance Misuse (CRISM; grant numbers CIS-144301, CIS-144302, CIS-144303, CIS-144304). The four nodes of CRISM received independent funding through a CIHR priority-driven initiative (grant numbers SMN-139148, SMN-139149, SMN-139150, SMN-139151).</p>
              </fn>
              <fn fn-type="other">
                <p><bold>ORCID iDs:</bold> Gabriel Bastien <ext-link xlink:href="https://orcid.org/0000-0002-7969-9998" ext-link-type="uri">https://orcid.org/0000-0002-7969-9998</ext-link></p>
                <p>Christina McAnulty <ext-link xlink:href="https://orcid.org/0000-0003-2787-2792" ext-link-type="uri">https://orcid.org/0000-0003-2787-2792</ext-link></p>
                <p>Didier Jutras-Aswad <ext-link xlink:href="https://orcid.org/0000-0002-8474-508X" ext-link-type="uri">https://orcid.org/0000-0002-8474-508X</ext-link></p>
              </fn>
              <fn fn-type="other">
                <p><bold>Supplemental Material:</bold> Supplemental material for this article is available online.</p>
              </fn>
            </fn-group>
            <ref-list>
              <title>References</title>
              <ref id="bibr1-07067437221145013">
                <label>1</label>
                <mixed-citation publication-type="book"><collab>Substance Abuse and Mental Health Services Administration</collab>. <source>Key substance use and mental health indicators in the United States: Results from the 2017 National Survey on Drug Use and Health</source>. <publisher-loc>Rockville</publisher-loc>, <publisher-loc>Maryland</publisher-loc>: <publisher-name>Center for Behaviorial Health Statistics and Quality, Substance Abuse and Mental Health Services Administration</publisher-name>; <year>2018</year>.</mixed-citation>
              </ref>
              <ref id="bibr2-07067437221145013">
                <label>2</label>
                <mixed-citation publication-type="book"><collab>United Nations Office on Drugs and Crime</collab>. <source>World Drug Report 2019 – Depressants</source>. <publisher-loc>Vienna</publisher-loc>: <publisher-name>United Nations publications</publisher-name>; <year>2019</year>.</mixed-citation>
              </ref>
              <ref id="bibr3-07067437221145013">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peles</surname><given-names>E</given-names></name><name><surname>Schreiber</surname><given-names>S</given-names></name><name><surname>Naumovsky</surname><given-names>Y</given-names></name><name><surname>Adelson</surname><given-names>M</given-names></name></person-group>. <article-title>Depression in methadone maintenance treatment patients: rate and risk factors</article-title>. <source>J Affect Disord</source>. <year>2007</year>;<volume>99</volume>(<issue>1–3</issue>):<fpage>213</fpage>-<lpage>220</lpage>.<pub-id pub-id-type="pmid">17055063</pub-id></mixed-citation>
              </ref>
              <ref id="bibr4-07067437221145013">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>AH</given-names></name><name><surname>Zvolensky</surname><given-names>MJ</given-names></name><name><surname>Ditre</surname><given-names>JW</given-names></name><name><surname>Buckner</surname><given-names>JD</given-names></name><name><surname>Asmundson</surname><given-names>GJG</given-names></name></person-group>. <article-title>Association of opioid misuse with anxiety and depression: a systematic review of the literature</article-title>. <source>Clin Psychol Rev</source>. <year>2021</year>;<volume>84</volume>:<fpage>101978</fpage>.<pub-id pub-id-type="pmid">33515811</pub-id></mixed-citation>
              </ref>
              <ref id="bibr5-07067437221145013">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassan</surname><given-names>AN</given-names></name>, <name><surname>Le Foll</surname><given-names>B</given-names></name></person-group>. <article-title>Survival probabilities and predictors of major depressive episode incidence among individuals with various types of substance use disorders</article-title>. <source>J Clin Psychiatry</source>. <year>2021</year>;<volume>82</volume>(<issue>5</issue>):<fpage>20m13637</fpage>.</mixed-citation>
              </ref>
              <ref id="bibr6-07067437221145013">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tetrault</surname><given-names>JM</given-names></name><name><surname>Fiellin</surname><given-names>DA</given-names></name></person-group>. <article-title>Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals</article-title>. <source>Drugs</source>. <year>2012</year>;<volume>72</volume>(<issue>2</issue>):<fpage>217</fpage>-<lpage>228</lpage>.<pub-id pub-id-type="pmid">22235870</pub-id></mixed-citation>
              </ref>
              <ref id="bibr7-07067437221145013">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murnion</surname><given-names>B</given-names></name></person-group>. <article-title>Management of opioid substitution therapy during medical intervention</article-title>. <source>Intern Med J</source>. <year>2012</year>;<volume>42</volume>(<issue>3</issue>):<fpage>242</fpage>-<lpage>246</lpage>.<pub-id pub-id-type="pmid">22432983</pub-id></mixed-citation>
              </ref>
              <ref id="bibr8-07067437221145013">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bart</surname><given-names>G</given-names></name><name><surname>Wyman</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Hodges</surname><given-names>JS</given-names></name><name><surname>Karim</surname><given-names>R</given-names></name><name><surname>Bart</surname><given-names>BA</given-names></name></person-group>. <article-title>Methadone and the QTc interval: paucity of clinically significant factors in a retrospective cohort</article-title>. <source>J Addict Med</source>. <year>2017</year>;<volume>11</volume>(<issue>6</issue>):<fpage>489</fpage>-<lpage>493</lpage>.<pub-id pub-id-type="pmid">28863009</pub-id></mixed-citation>
              </ref>
              <ref id="bibr9-07067437221145013">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuten</surname><given-names>M</given-names></name><name><surname>DeFulio</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>HE</given-names></name><name><surname>Stitzer</surname><given-names>M</given-names></name></person-group>. <article-title>Abstinence-contingent recovery housing and reinforcement-based treatment following opioid detoxification</article-title>. <source>Addiction</source>. <year>2012</year>;<volume>107</volume>(<issue>5</issue>):<fpage>973</fpage>-<lpage>982</lpage>.<pub-id pub-id-type="pmid">22151478</pub-id></mixed-citation>
              </ref>
              <ref id="bibr10-07067437221145013">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tenore</surname><given-names>PL</given-names></name></person-group>. <article-title>Psychotherapeutic benefits of opioid agonist therapy</article-title>. <source>J Addict Dis</source>. <year>2008</year>;<volume>27</volume>(<issue>3</issue>):<fpage>49</fpage>-<lpage>65</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr11-07067437221145013">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emrich</surname><given-names>HM</given-names></name><name><surname>Vogt</surname><given-names>P</given-names></name><name><surname>Herz</surname><given-names>A</given-names></name></person-group>. <article-title>Possible antidepressive effects of opioids: action of buprenorphine</article-title>. <source>Ann N Y Acad Sci</source>. <year>1982</year>;<volume>398</volume>:<fpage>108</fpage>-<lpage>112</lpage>.<pub-id pub-id-type="pmid">6760767</pub-id></mixed-citation>
              </ref>
              <ref id="bibr12-07067437221145013">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bodkin</surname><given-names>JA</given-names></name><name><surname>Zornberg</surname><given-names>GL</given-names></name><name><surname>Lukas</surname><given-names>SE</given-names></name><name><surname>Cole</surname><given-names>JO</given-names></name></person-group>. <article-title>Buprenorphine treatment of refractory depression</article-title>. <source>J Clin Psychopharmacol</source>. <year>1995</year>;<volume>15</volume>(<issue>1</issue>):<fpage>49</fpage>-<lpage>57</lpage>.<pub-id pub-id-type="pmid">7714228</pub-id></mixed-citation>
              </ref>
              <ref id="bibr13-07067437221145013">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Callawaye</surname><given-names>EJBP</given-names></name></person-group>. <article-title>Buprenorphine for depression</article-title>. <source>Comparative Study</source>. <year>1996</year>;<volume>39</volume>(<issue>12</issue>):<fpage>989</fpage>-<lpage>990</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr14-07067437221145013">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mongan</surname><given-names>L</given-names></name><name><surname>Callaway</surname><given-names>EJBP</given-names></name></person-group>. <article-title>Buprenorphine responders</article-title>. <source>Biol Psychiatry</source>. <year>1990</year>;<volume>28</volume>(<issue>12</issue>):<fpage>1078</fpage>-<lpage>1080</lpage>.<pub-id pub-id-type="pmid">2289007</pub-id></mixed-citation>
              </ref>
              <ref id="bibr15-07067437221145013">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>S</given-names></name><name><surname>Benhamou</surname><given-names>O-M</given-names></name></person-group>. <article-title>Depression: what’s Buprenorphine got to do with it?</article-title><source>Am J Psychiatry Resid J</source>. <year>2019</year>;<volume>14</volume>(<issue>2</issue>):<fpage>5</fpage>-<lpage>7</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr16-07067437221145013">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kosten</surname><given-names>TR</given-names></name><name><surname>Morgan</surname><given-names>C</given-names></name><name><surname>Kosten</surname><given-names>TA</given-names></name></person-group>. <article-title>Depressive symptoms during buprenorphine treatment of opioid abusers</article-title>. <source>J Subst Abuse Treat</source>. <year>1990</year>;<volume>7</volume>(<issue>1</issue>):<fpage>51</fpage>-<lpage>54</lpage>.<pub-id pub-id-type="pmid">2313769</pub-id></mixed-citation>
              </ref>
              <ref id="bibr17-07067437221145013">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maremmani</surname><given-names>I</given-names></name>, <name><surname>Pacini</surname><given-names>M</given-names></name>, <name><surname>Pani</surname><given-names>PP</given-names></name></person-group>. <article-title>Effectiveness of buprenorphine in double diagnosed patients. Buprenorphine as psychothropic drug</article-title>. <source>Heroin Add Rel Clin Probl</source>. <year>2006</year>;<volume>8</volume>(<issue>1</issue>):<fpage>31</fpage>-<lpage>48</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr18-07067437221145013">
                <label>18</label>
                <mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Kamajian</surname><given-names>G</given-names></name><name><surname>Cable</surname><given-names>R</given-names></name><name><surname>Greco</surname><given-names>J</given-names></name><name><surname>Laughlin</surname><given-names>B</given-names></name><name><surname>deGroot</surname><given-names>T</given-names></name></person-group>. <comment>Off Label Use of Suboxone for Treatment Resistant Depression; 2016</comment>.</mixed-citation>
              </ref>
              <ref id="bibr19-07067437221145013">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karp</surname><given-names>JF</given-names></name><name><surname>Butters</surname><given-names>MA</given-names></name><name><surname>Begley</surname><given-names>AE</given-names></name></person-group>, <etal>et al.</etal><article-title>Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults</article-title>. <source>J Clin Psychiatry</source>. <year>2014</year>;<volume>75</volume>(<issue>8</issue>):<fpage>e785</fpage>-<lpage>e793</lpage>.<pub-id pub-id-type="pmid">25191915</pub-id></mixed-citation>
              </ref>
              <ref id="bibr20-07067437221145013">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dean</surname><given-names>A</given-names></name><name><surname>Bell</surname><given-names>J</given-names></name><name><surname>Mascord</surname><given-names>DJ</given-names></name><name><surname>Parker</surname><given-names>G</given-names></name><name><surname>Christie</surname><given-names>MJ</given-names></name></person-group>. <article-title>A randomised, controlled trial of fluoxetine in methadone maintenance patients with depressive symptoms</article-title>. <source>J Affect Disord</source>. <year>2002</year>;<volume>72</volume>(<issue>1</issue>):<fpage>85</fpage>-<lpage>90</lpage>.<pub-id pub-id-type="pmid">12204321</pub-id></mixed-citation>
              </ref>
              <ref id="bibr21-07067437221145013">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dyer</surname><given-names>KR</given-names></name><name><surname>White</surname><given-names>JM</given-names></name><name><surname>Foster</surname><given-names>DJ</given-names></name><name><surname>Bochner</surname><given-names>F</given-names></name><name><surname>Menelaou</surname><given-names>A</given-names></name><name><surname>Somogyi</surname><given-names>AA</given-names></name></person-group>. <article-title>The relationship between mood state and plasma methadone concentration in maintenance patients</article-title>. <source>J Clin Psychopharmacol</source>. <year>2001</year>;<volume>21</volume>(<issue>1</issue>):<fpage>78</fpage>-<lpage>84</lpage>.<pub-id pub-id-type="pmid">11199952</pub-id></mixed-citation>
              </ref>
              <ref id="bibr22-07067437221145013">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammadi</surname><given-names>M</given-names></name><name><surname>Kazeminia</surname><given-names>M</given-names></name><name><surname>Abdoli</surname><given-names>N</given-names></name></person-group>, <etal>et al.</etal><article-title>The effect of methadone on depression among addicts: a systematic review and meta-analysis</article-title>. <source>Health Qual Life Outcomes</source>. <year>2020</year>;<volume>18</volume>(<issue>1</issue>):<fpage>373</fpage>.<pub-id pub-id-type="pmid">33225933</pub-id></mixed-citation>
              </ref>
              <ref id="bibr23-07067437221145013">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mague</surname><given-names>SD</given-names></name><name><surname>Pliakas</surname><given-names>AM</given-names></name><name><surname>Todtenkopf</surname><given-names>MS</given-names></name></person-group>, <etal>et al.</etal><article-title>Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats</article-title>. <source>J Pharmacol Exp Ther</source>. <year>2003</year>;<volume>305</volume>(<issue>1</issue>):<fpage>323</fpage>-<lpage>330</lpage>.<pub-id pub-id-type="pmid">12649385</pub-id></mixed-citation>
              </ref>
              <ref id="bibr24-07067437221145013">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dean</surname><given-names>A</given-names></name><name><surname>Bell</surname><given-names>J</given-names></name><name><surname>Christie</surname><given-names>M</given-names></name><name><surname>Mattick</surname><given-names>RP</given-names></name></person-group>. <article-title>Depressive symptoms during buprenorphine vs. Methadone maintenance: findings from a randomised, controlled trial in opioid dependence</article-title>. <source>Eur Psychiatry</source>. <year>2004</year>;<volume>19</volume>(<issue>8</issue>):<fpage>510</fpage>-<lpage>513</lpage>. <pub-id pub-id-type="pmid">15589713</pub-id></mixed-citation>
              </ref>
              <ref id="bibr25-07067437221145013">
                <label>25</label>
                <mixed-citation publication-type="book"><collab>National Academies of Sciences E, Medicine</collab>. <source>Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use</source>. <publisher-loc>Washington</publisher-loc>, <publisher-loc>DC</publisher-loc>: <publisher-name>The National Academies Press</publisher-name>; <year>2017</year>.</mixed-citation>
              </ref>
              <ref id="bibr26-07067437221145013">
                <label>26</label>
                <mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>C</given-names></name></person-group>. <comment>Trends in the distribution of selected opioids by state, US, 1999–2011. National Meeting Safe States Alliance Baltimore: National Center for Injury Prevention and Control; 2013</comment>.</mixed-citation>
              </ref>
              <ref id="bibr27-07067437221145013">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peckham</surname><given-names>AD</given-names></name><name><surname>Griffin</surname><given-names>ML</given-names></name><name><surname>McHugh</surname><given-names>RK</given-names></name><name><surname>Weiss</surname><given-names>RD</given-names></name></person-group>. <article-title>Depression history as a predictor of outcomes during buprenorphine-naloxone treatment of prescription opioid use disorder</article-title>. <source>Drug Alcohol Depend</source>. <year>2020</year>;<volume>213</volume>:<fpage>108122</fpage>.<pub-id pub-id-type="pmid">32563846</pub-id></mixed-citation>
              </ref>
              <ref id="bibr28-07067437221145013">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Socias</surname><given-names>ME</given-names></name><name><surname>Ahamad</surname><given-names>K</given-names></name><name><surname>Le Foll</surname><given-names>B</given-names></name></person-group>, <etal>et al.</etal><article-title>The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: study design and rationale</article-title>. <source>Contemp Clin Trials</source>. <year>2018</year>;<volume>69</volume>:<fpage>21</fpage>-<lpage>27</lpage>.<pub-id pub-id-type="pmid">29627621</pub-id></mixed-citation>
              </ref>
              <ref id="bibr29-07067437221145013">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jutras-Aswad</surname><given-names>D</given-names></name><name><surname>Le Foll</surname><given-names>B</given-names></name><name><surname>Ahamad</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal><article-title>Flexible buprenorphine/naloxone model of care for reducing opioid use in individuals with prescription-type opioid use disorder: an open-label, pragmatic, noninferiority randomized controlled trial</article-title>. <source>Am J Psychiatry</source>. <year>2022</year>:<fpage>appiajp21090964</fpage>.</mixed-citation>
              </ref>
              <ref id="bibr30-07067437221145013">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bates</surname><given-names>D</given-names></name>, <name><surname>Maechler</surname><given-names>M</given-names></name>, <name><surname>Bolker</surname><given-names>B</given-names></name>, <name><surname>Walker</surname><given-names>S</given-names></name></person-group>. <article-title>lme4: Linear mixed-effects models using Eigen and S4</article-title>. <source>R package version 1.1-10</source>. <year>2015</year>. <ext-link xlink:href="http://CRAN.R-project.org/package=lme4." ext-link-type="uri">http://CRAN.R-project.org/package= lme4.</ext-link></mixed-citation>
              </ref>
              <ref id="bibr31-07067437221145013">
                <label>31</label>
                <mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Tingley</surname><given-names>D</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Hirose</surname><given-names>K</given-names></name><name><surname>Keele</surname><given-names>L</given-names></name><name><surname>Imai</surname><given-names>K</given-names></name></person-group>. <comment>Mediation: R package for causal mediation analysis. 2014</comment>.</mixed-citation>
              </ref>
              <ref id="bibr32-07067437221145013">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scherrer</surname><given-names>JF</given-names></name><name><surname>Svrakic</surname><given-names>DM</given-names></name><name><surname>Freedland</surname><given-names>KE</given-names></name></person-group>, <etal>et al.</etal><article-title>Prescription opioid analgesics increase the risk of depression</article-title>. <source>J Gen Intern Med</source>. <year>2014</year>;<volume>29</volume>(<issue>3</issue>):<fpage>491</fpage>-<lpage>499</lpage>.<pub-id pub-id-type="pmid">24165926</pub-id></mixed-citation>
              </ref>
              <ref id="bibr33-07067437221145013">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scherrer</surname><given-names>JF</given-names></name><name><surname>Salas</surname><given-names>J</given-names></name><name><surname>Copeland</surname><given-names>LA</given-names></name></person-group>, <etal>et al.</etal><article-title>Increased risk of depression recurrence after initiation of prescription opioids in noncancer pain patients</article-title>. <source>J Pain</source>. <year>2016</year>;<volume>17</volume>(<issue>4</issue>):<fpage>473</fpage>-<lpage>482</lpage>.<pub-id pub-id-type="pmid">26884282</pub-id></mixed-citation>
              </ref>
              <ref id="bibr34-07067437221145013">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>J</given-names></name>, <name><surname>Santo</surname><given-names>T</given-names></name>, <name><surname>Colledge</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>Mood and anxiety symptoms in persons taking prescription opioids: a systematic review with meta-analyses of longitudinal studies</article-title>. <source>Pain Med</source>. <year>2022</year>;<volume>23</volume><issue>(8)</issue>:<fpage>1442</fpage>-<lpage>1456</lpage>.<pub-id pub-id-type="pmid">35167694</pub-id></mixed-citation>
              </ref>
              <ref id="bibr35-07067437221145013">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merza</surname><given-names>Z</given-names></name></person-group>. <article-title>Chronic use of opioids and the endocrine system</article-title>. <source>Horm Metab Res</source>. <year>2010</year>;<volume>42</volume>(<issue>9</issue>):<fpage>621</fpage>-<lpage>626</lpage>.<pub-id pub-id-type="pmid">20486065</pub-id></mixed-citation>
              </ref>
              <ref id="bibr36-07067437221145013">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hallinan</surname><given-names>R</given-names></name><name><surname>Byrne</surname><given-names>A</given-names></name><name><surname>Agho</surname><given-names>K</given-names></name><name><surname>McMahon</surname><given-names>CG</given-names></name><name><surname>Tynan</surname><given-names>P</given-names></name><name><surname>Attia</surname><given-names>J</given-names></name></person-group>. <article-title>Hypogonadism in men receiving methadone and buprenorphine maintenance treatment</article-title>. <source>Int J Androl</source>. <year>2009</year>;<volume>32</volume>(<issue>2</issue>):<fpage>131</fpage>-<lpage>139</lpage>.<pub-id pub-id-type="pmid">17971165</pub-id></mixed-citation>
              </ref>
              <ref id="bibr37-07067437221145013">
                <label>37</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McAnulty</surname><given-names>C</given-names></name><name><surname>Bastien</surname><given-names>G</given-names></name><name><surname>Eugenia Socias</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Buprenorphine/naloxone and methadone effectiveness for reducing craving in individuals with prescription opioid use disorder: exploratory results from an open-label, pragmatic randomized controlled trial</article-title>. <source>Drug Alcohol Depend</source>. <year>2022</year>;<volume>239</volume>:<fpage>109604</fpage>.<pub-id pub-id-type="pmid">36037586</pub-id></mixed-citation>
              </ref>
              <ref id="bibr38-07067437221145013">
                <label>38</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pergolizzi</surname><given-names>JV</given-names><suffix>Jr</suffix></name><name><surname>Raffa</surname><given-names>RB</given-names></name><name><surname>Rosenblatt</surname><given-names>MH</given-names></name></person-group>. <article-title>Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: current understanding and approaches to management</article-title>. <source>J Clin Pharm Ther</source>. <year>2020</year>;<volume>45</volume>(<issue>5</issue>):<fpage>892</fpage>-<lpage>903</lpage>.<pub-id pub-id-type="pmid">31986228</pub-id></mixed-citation>
              </ref>
              <ref id="bibr39-07067437221145013">
                <label>39</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torres-Lockhart</surname><given-names>KE</given-names></name><name><surname>Lu</surname><given-names>TY</given-names></name><name><surname>Weimer</surname><given-names>MB</given-names></name><name><surname>Stein</surname><given-names>MR</given-names></name><name><surname>Cunningham</surname><given-names>CO</given-names></name></person-group>. <article-title>Clinical management of opioid withdrawal</article-title>. <source>Addiction</source>. <year>2022</year>;<volume>117</volume>(<issue>9</issue>):<fpage>2540</fpage>-<lpage>2550</lpage>.<pub-id pub-id-type="pmid">35112746</pub-id></mixed-citation>
              </ref>
              <ref id="bibr40-07067437221145013">
                <label>40</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benedetti</surname><given-names>F</given-names></name><name><surname>Carlino</surname><given-names>E</given-names></name><name><surname>Piedimonte</surname><given-names>A</given-names></name></person-group>. <article-title>Increasing uncertainty in CNS clinical trials: the role of placebo, nocebo, and Hawthorne effects</article-title>. <source>Lancet Neurol</source>. <year>2016</year>;<volume>15</volume>(<issue>7</issue>):<fpage>736</fpage>-<lpage>747</lpage>.<pub-id pub-id-type="pmid">27106073</pub-id></mixed-citation>
              </ref>
              <ref id="bibr41-07067437221145013">
                <label>41</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Momeni</surname><given-names>F</given-names></name><name><surname>Moshtagh</surname><given-names>N</given-names></name><name><surname>Pourshahbaz</surname><given-names>AJ</given-names></name></person-group>. <article-title>Effectiveness of cognitive-behavioral group therapy on craving, depression &amp; anxiety among the opiate abusers under MMT</article-title>. <source>Iran Rehabil J</source>. <year>2010</year>;<volume>8</volume>(<issue>1</issue>):<fpage>19</fpage>-<lpage>23</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr42-07067437221145013">
                <label>42</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicholson</surname><given-names>HL</given-names></name></person-group>. <article-title>Socioeconomic status, fundamental cause theory, and prescription opioid use behaviors: a theoretical examination</article-title>. <source>Sociol Spectr</source>. <year>2020</year>;<volume>40</volume>(<issue>1</issue>):<fpage>1</fpage>-<lpage>32</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr43-07067437221145013">
                <label>43</label>
                <mixed-citation publication-type="other"><collab>Centers for Disease Control and Prevention</collab>. <comment>2018 Annual surveillance report of drug-related risks and outcomes. 2018</comment>. <ext-link xlink:href="https://www.cdc.gov/drugoverdose/pdf/pubs/2018-cdc-drug-surveillance-report.pdf" ext-link-type="uri">https://www.cdc.gov/drugoverdose/pdf/pubs/2018-cdc-drug-surveillance-report.pdf</ext-link>.</mixed-citation>
              </ref>
              <ref id="bibr44-07067437221145013">
                <label>44</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feldman</surname><given-names>CH</given-names></name><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Katz</surname><given-names>JN</given-names></name><name><surname>Donnell-Fink</surname><given-names>LA</given-names></name><name><surname>Losina</surname><given-names>E</given-names></name></person-group>. <article-title>Association between socioeconomic status and pain, function and pain catastrophizing at presentation for total knee arthroplasty</article-title>. <source>BMC Musculoskelet Disord</source>. <year>2015</year>;<volume>16</volume>(<issue>1</issue>):<fpage>18</fpage>.<pub-id pub-id-type="pmid">25768862</pub-id></mixed-citation>
              </ref>
              <ref id="bibr45-07067437221145013">
                <label>45</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Compton</surname><given-names>WM</given-names></name><name><surname>Jones</surname><given-names>CM</given-names></name><name><surname>Baldwin</surname><given-names>GT</given-names></name></person-group>. <article-title>Relationship between nonmedical prescription-opioid use and heroin use</article-title>. <source>N Engl J Med</source>. <year>2016</year>;<volume>374</volume>(<issue>2</issue>):<fpage>154</fpage>-<lpage>163</lpage>.<pub-id pub-id-type="pmid">26760086</pub-id></mixed-citation>
              </ref>
              <ref id="bibr46-07067437221145013">
                <label>46</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>C</given-names></name><name><surname>El-Gabalawy</surname><given-names>R</given-names></name><name><surname>Keyes</surname><given-names>KM</given-names></name><name><surname>Martins</surname><given-names>SS</given-names></name><name><surname>Sareen</surname><given-names>J</given-names></name></person-group>. <article-title>Risk factors for incident nonmedical prescription opioid use and abuse and dependence: results from a longitudinal nationally representative sample</article-title>. <source>Drug Alcohol Depend</source>. <year>2013</year>;<volume>132</volume>(<issue>1</issue>):<fpage>107</fpage>-<lpage>113</lpage>.<pub-id pub-id-type="pmid">23399466</pub-id></mixed-citation>
              </ref>
              <ref id="bibr47-07067437221145013">
                <label>47</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bedene</surname><given-names>A</given-names></name><name><surname>Lijfering</surname><given-names>WM</given-names></name><name><surname>Niesters</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Opioid prescription patterns and risk factors associated with opioid use in the Netherlands</article-title>. <source>JAMA Network Open</source>. <year>2019</year>;<volume>2</volume>(<issue>8</issue>):<fpage>e1910223</fpage>.<pub-id pub-id-type="pmid">31461149</pub-id></mixed-citation>
              </ref>
              <ref id="bibr48-07067437221145013">
                <label>48</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattick</surname><given-names>RP</given-names></name><name><surname>Breen</surname><given-names>C</given-names></name><name><surname>Kimber</surname><given-names>J</given-names></name><name><surname>Davoli</surname><given-names>M</given-names></name></person-group>. <article-title>Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2014</year>;<volume>2</volume>: <fpage>CD002207</fpage>.</mixed-citation>
              </ref>
              <ref id="bibr49-07067437221145013">
                <label>49</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maremmani</surname><given-names>I</given-names></name><name><surname>Gerra</surname><given-names>G</given-names></name></person-group>. <article-title>Buprenorphine-based regimens and methadone for the medical management of opioid dependence: selecting the appropriate drug for treatment</article-title>. <source>Am J Addict</source>. <year>2010</year>;<volume>19</volume>(<issue>6</issue>):<fpage>557</fpage>-<lpage>568</lpage>.<pub-id pub-id-type="pmid">20958853</pub-id></mixed-citation>
              </ref>
              <ref id="bibr50-07067437221145013">
                <label>50</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonhomme</surname><given-names>J</given-names></name><name><surname>Shim</surname><given-names>RS</given-names></name><name><surname>Gooden</surname><given-names>R</given-names></name><name><surname>Tyus</surname><given-names>D</given-names></name><name><surname>Rust</surname><given-names>G</given-names></name></person-group>. <article-title>Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options</article-title>. <source>J Natl Med Assoc</source>. <year>2012</year>;<volume>104</volume>(<issue>7–8</issue>):<fpage>342</fpage>-<lpage>350</lpage>.<pub-id pub-id-type="pmid">23092049</pub-id></mixed-citation>
              </ref>
              <ref id="bibr51-07067437221145013">
                <label>51</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lutfy</surname><given-names>K</given-names></name><name><surname>Cowan</surname><given-names>A</given-names></name></person-group>. <article-title>Buprenorphine: a unique drug with complex pharmacology</article-title>. <source>Curr Neuropharmacol</source>. <year>2004</year>;<volume>2</volume>(<issue>4</issue>):<fpage>395</fpage>-<lpage>402</lpage>.<pub-id pub-id-type="pmid">18997874</pub-id></mixed-citation>
              </ref>
              <ref id="bibr52-07067437221145013">
                <label>52</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melichar</surname><given-names>JK</given-names></name><name><surname>Hume</surname><given-names>SP</given-names></name><name><surname>Williams</surname><given-names>TM</given-names></name></person-group>, <etal>et al.</etal><article-title>Using [<sup>11</sup>C]diprenorphine to image opioid receptor occupancy by methadone in opioid addiction: clinical and preclinical studies</article-title>. <source>J Pharmacol Exp Ther</source>. <year>2005</year>;<volume>312</volume>(<issue>1</issue>):<fpage>309</fpage>-<lpage>315</lpage>.<pub-id pub-id-type="pmid">15347732</pub-id></mixed-citation>
              </ref>
              <ref id="bibr53-07067437221145013">
                <label>53</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>A</given-names></name><name><surname>Kahan</surname><given-names>M</given-names></name><name><surname>Nader</surname><given-names>M</given-names></name></person-group>. <article-title>Primary care management of opioid use disorders: abstinence, methadone, or buprenorphine-naloxone?</article-title><source>Can Fam Physician</source>. <year>2017</year>;<volume>63</volume>(<issue>3</issue>):<fpage>200</fpage>-<lpage>205</lpage>.<pub-id pub-id-type="pmid">28292795</pub-id></mixed-citation>
              </ref>
              <ref id="bibr54-07067437221145013">
                <label>54</label>
                <mixed-citation publication-type="other"><collab>CRISM National Guideline Review Committee</collab>. <comment>CRISM National Guidelines for the Clinical Management of Opioid Use Disorder. 2018</comment>. <ext-link xlink:href="https://crism.ca/wp-content/uploads/2018/03/CRISM_NationalGuideline_OUD-ENG.pdf" ext-link-type="uri">https://crism.ca/wp-content/uploads/2018/03/CRISM_NationalGuideline_OUD-ENG.pdf</ext-link>.</mixed-citation>
              </ref>
              <ref id="bibr55-07067437221145013">
                <label>55</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Checkley</surname><given-names>L</given-names></name><name><surname>Steiger</surname><given-names>S</given-names></name><name><surname>Knight</surname><given-names>KR</given-names></name></person-group>. <article-title>“I wanted something that was more flexible”: a qualitative study of patient preferences on choosing buprenorphine over methadone in a large, safety-net hospital opioid treatment program</article-title>. <source>Subst Abus</source>. <year>2022</year>;<volume>43</volume>(<issue>1</issue>):<fpage>767</fpage>-<lpage>773</lpage>.<pub-id pub-id-type="pmid">35112998</pub-id></mixed-citation>
              </ref>
              <ref id="bibr56-07067437221145013">
                <label>56</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yarborough</surname><given-names>BJH</given-names></name><name><surname>Stumbo</surname><given-names>SP</given-names></name><name><surname>McCarty</surname><given-names>D</given-names></name><name><surname>Mertens</surname><given-names>J</given-names></name><name><surname>Weisner</surname><given-names>C</given-names></name><name><surname>Green</surname><given-names>CA</given-names></name></person-group>. <article-title>Methadone, buprenorphine and preferences for opioid agonist treatment: a qualitative analysis</article-title>. <source>Drug Alcohol Depend</source>. <year>2016</year>;<volume>160</volume>:<fpage>112</fpage>-<lpage>118</lpage>.<pub-id pub-id-type="pmid">26796596</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
